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ABSTRACT OF THE DISSERTATION
MYCOBACTERIUM TUBERCULOSIS INHIBITORS: ACTION AND
RESISTANCE
By
Pamela K. Garcia-Moreno
Florida International University, 2018
Miami, Florida
Professor Yuk-Ching Tse-Dinh, Major Professor
Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis, has
been a global health problem for years. The emergence of drug resistance in this organism
generates the necessity of exploring novel targets and developing new drugs.
Topoisomerases are enzymes found in all kingdoms of life responsible for overcoming the
topological barriers encountered during essential cellular processes. The genomes of
mycobacteria encode only one type IA topoisomerase (MtopI), which has been validated
as a novel TB drug target. The goal of this study is to obtain new information on the
mechanism and resistance of endogenous and synthetic inhibitors of MtopI.
Rv1495 is a M. tuberculosis toxin that belongs to the MazEF family (MazE is the
antitoxin and MazF is the toxin), with endoribonuclease activity. Rv1495 (MazF homolog
in M. tuberculosis) toxin has been shown to interact directly with the C-terminal domain
of MtopI for mutual inhibition. In this study the interaction of Rv1495 with the positively
charged C-terminal tail in Mtop I is reported. This new information is useful for rational
design and discovery of antibiotics for mycobacteria.
Ethacridine, an FDA approved drug has shown activity against MtopI. In this
project we studied the mechanisms of resistance associated with this drug as well the use
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of Ethacridine in combination with Moxifloxacin, to potentiate the bactericidal effect of
this current second line drug for TB treatment. Results from sequencing of the genomic
DNA isolated from the resistant mutants suggested the involvement of the Hollidayjunction Ruv resolvase. Further studies showed that co-treatment with Ethacridine can
enhance the moxifloxacin-mediated killing of M. smegmatis.
FP-11g, a novel fluoroquinophenoxazine inhibitor of bacterial topoisomerase I, has
shown promising activity against M, tuberculosis. We explored the bactericidal activity
and resistance mechanisms associated to FP-11g using M. smegmatis as model organism.
Additionally, the inhibitory effect of FP-11g was also evaluated on M. abscessus. FP-11g
at concentration 4X MIC showed complete bactericidal activity against M. smegmatis after
24 hours. Inhibitory activity against M. abscessus was also observed. Results from
sequencing of the genomic DNA isolated from the M. smegmatis resistant mutants revealed
mutations in genes associated with general drug resistance.
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1. INTRODUCTION
In general, any disease or health disorder not related to bacterial infection could
potentially be associated with bacterial infections. For instance, patients that suffer diabetes,
HIV (Human Immunodeficiency Virus), cirrhosis, hematologic diseases, organ
transplantation, drug addiction, traffic accidents, home accidents, work accidents,
immunodeficiency diseases (lupus, arthritis, cancer and so on), and more prevalent,
patients secluded in a hospital for long stays (nosocomial infections) or surgeries are at risk
of developing a bacterial infection. On the other hand, bacterial infections can be the
primary cause of the pathology and can be self-limited or require antibiotics for resolution;
for instance, food poisoning. Our ability to control pathogenic organisms rests with our
capacity of preventing infections and resolve infections using antibiotics.
The massive use of antibiotics in human health and animal health/production has
generated a frightening increase in the drug resistance to diverse antibiotics(Van Puyvelde,
Deborggraeve et al. 2018). Two punctual examples are the use of fluoroquinolones and
oxytetracyclines in fish farming (Cantas, Shah et al. 2013) and the indiscriminate use of
antibiotics in clinical settings to “resolve” infections with a non-bacterial etiology; both
generate an imbalance and play a role in the selection and spreading of drug resistance. A
substantial effort has been invested in decreasing the use of antibiotics through education
and public policies in some countries, but there is a long way to go, especially with training
for adequate antibiotic prescriptions by physicians and the use of antibiotics in animal
production in developing countries and countries with high demand for animal-derived
products.
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Although control of the use of antibiotics is a very important initiative to decrease and
prevent the drug resistance, the study of novel targets, design and finding of new drugs is
also a priority; studies have shown that the persistence of antibiotic resistance even if we
reduce the use of antibiotics will continue since those resistant mutants will not disappear
that easy (Andersson and Hughes 2011). Indeed, the need for new antimicrobial agents is
urgent.
The last report published by WHO (World Health Organization) “Global Priority List
of Antibiotic-resistant Bacteria to Guide Research, Discovery, and Development of New
Antibiotics” (World Health Organization 2017) summarizes the critical, high and medium
priorities in regard to bacterial agents. In the WHO report Mycobacterium tuberculosis
does not appear listed; but a note is included mentioning that the organism is already a
global priority classified in the critical category. In fact, every year an extensive report of
tuberculosis (TB) is created by the WHO to update statistics about the improvements and
main needs in the battle against this global public health problem.
Tuberculosis is an infectious disease caused by M. tuberculosis; most of the cases are
related to pulmonary disease. However, the organism can affect any organ (extrapulmonary
TB) including skin, bones, lymph nodes, meninges, liver, gastrointestinal mucosa, etc.
Extrapulmonary

TB

seems

to

be

associated

with

infant,

elderly

and

the

immunocompromised population (Gray and Cohn 2013, Boisson-Dupuis, Bustamante et
al. 2015, Gounder, Moodley et al. 2017, Shivakoti, Sharma et al. 2017), while pulmonary
TB is also widely spread in immunocompetent individuals.
The last TB report published by the World Health Organization (WHO) shows that we
are still far from the complete elimination of this disease; Although, the estimated target
by 2030 is the reduction of deaths associated with TB in 90% and the incidence in 80%,
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previous reports estimated the same for 2015; much must be done to obtain these goals.
Tuberculosis ranks above HIV/SIDA as the ninth cause of death associated with an
infectious agent; an estimated incidence of 10.4 million cases was reported in 2016 where
56% of cases would correspond to India, Indonesia, China, the Philippines and Pakistan.
Additionally, 1.3 million deaths in HIV-negative people as well as 374,000 deaths in HIVpositive population were reported for 2016 and 490,000 cases of Multidrug-Resistance
(MDR) (World Health Organization 2017 ).
Drug resistance is an important problem despite the efficiency of the first line drugs
currently available for TB treatment. The causes for resistance are diverse: poor adherence
to the treatment considering it takes a long time and generates side effects, poor quality of
drugs, treatment of sensitive strains using drug regimens for drug resistant strains,
transmission of the microorganisms in public places, among others. The first line drugs
group includes Isoniazid (INH), Rifampicin (RIF), Ethambutol (EMB) and Pyrazinamide
(PZA); these are the first choice when an active infection is diagnosed clinically or through
laboratory tests. First-line drugs are the most effective known drugs against M. tuberculosis.
However, if the bacteria develop resistance to the first line group of drugs, the second line
drugs are the next choice; they are not as efficient in the elimination of the microorganism
as first line drugs. Second-line drugs include fluoroquinolones, aminoglycosides and
cyclic peptides, which are drugs used also in other bacterial infections but have shown
good activity against M. tuberculosis.
MDR (Multi Drug Resistant), XDR (Extremely Drug Resistant) and TDR (Totally
Drug Resistant Strains) are the current classification of the levels of resistance to first and
second line drugs in TB. The MDR strains are resistant to INH and RIF; XDR strains are
resistant to at least INH and RIF, to any fluoroquinolones and to any second line injectable;
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Lastly, TDR strains are resistant to all the currently drugs available for TB treatment
((CDC) 2006, World Health Organization 2006, Migliori, De Iaco et al. 2007, Migliori,
Ortmann et al. 2007, Velayati, Masjedi et al. 2009). All these categories of resistance in M.
tuberculosis, especially the already described TDR, generate the urgent necessity of
exploring novel targets and development of new drugs.
In the last 40 years, only Bedaquiline and Delamanid have been approved for use in the
TB treatment regimen as an alternative to the current treatment under specific regulations
and in some countries (Gler, Skripconoka et al. 2012, Lessem, Cox et al. 2015, Zumla,
Chakaya et al. 2015). Indeed, there are 17 drugs in phase I, II or III trials and various new
combinations are being tested (Laughon and Nacy 2017, World Health Organization 2017 )
Figure 1. Drug development must continue to deal with drug resistance to current drugs
and new drugs since bacteria are smart enough to develop very sophisticated resistance
mechanisms.

Figure 1. Current anti-TB drugs pipeline
Drugs against M. tuberculosis are emerging after 5 decades of inactivity. Some are
repurposed drugs (fluoroquinolones, rifamycins and oxazolidinones) and others new
drugs such as Bedaquiline and Delamanid, which have been approved for treatment of
MDR-TB cases by the US Food and Drug Administration. (Zumla, Nahid et al. 2013)
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To maintain a productive drug pipeline for TB, clinical studies of promising drugs and
basic studies about M. tuberculosis pathogenesis, novel targets, essential genes and
mechanism of resistance in mycobacteria are imperative to continue the battle against this
infectious disease.
The drugs currently used in TB treatment have different targets in the bacteria; INH
targets the Enoyl-acyl carrier protein reductase (inhA), important in the fatty acid
biosynthesis pathway (Marrakchi, Laneelle et al. 2000), RIF targets RNA
polymerase(Levin and Hatfull 1993, Horng, Jeng et al. 2015), EMB targets the arabinosyl
transferase responsible for the polymerization of arabinose into arabinan (Belanger, Besra
et al. 1996) and PZA inhibits multiple targets, among those the ribosomal protein S1
(RpsA) (Cole 2011, Zhang, Shi et al. 2014). On the other hand, second-line drugs,
fluoroquinolones, aminoglycosides and cyclic peptides, targets DNA gyrase (Drlica and
Malik 2003, Mdluli and Ma 2007), 30S ribosomal subunit (16SrRNA) (Wilson 2014) and
diverse important proteins in the cell, respectively. However, as stated before, resistance
to most of the current antibiotics against M. tuberculosis has been identified.
Another important group of mycobacteria that are becoming a health problem in United
States correspond to Non-tuberculous Mycobacteria (NTM). Infections caused by NTM
are more difficult to treat than TB, especially because of the intrinsic resistance of these
organisms to many currently available drugs. The NTM are opportunistic organism found
in the environment, soil and water. A recent report shows an increment in the reporting
frequency of infections caused by NTM between 1994 and 2014 from four states in the
United States. The more prevalent strains correspond to M. chelonae-abscessus group, M.
fortuitum group and M. avium complex with increments of 322%, 194% and 149%,
respectively (Figure 2) (Donohue 2018).
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These opportunistic pathogens affect mainly people with predisposed conditions or
after surgical interventions (wounds). People suffering chronic diseases such as Cystic
Fibrosis, Chronic Obstructive Pulmonary Disease (COPD) and AIDS are more vulnerable
to infections caused by NTM. Cystic Fibrosis is an autosomal recessive disorder common
in regions with northern European ancestry such as North America, Australia and Europe
(Elborn 2016). The consequences of this condition include accumulation of mucus in the
lungs and chronic infections: M. abscessus complex and M. avium complex are the most
common species of NTM isolated in these patients (Furukawa and Flume 2018, Gardner,
McClenaghan et al. 2018).

Figure 2. Increment of infections caused by NTM in United States.
Report of infections caused by NTM in 1994 and 2014 in four states: Mississippi,
Missouri, Ohio and Wisconsin (rate per 100,000 persons). M. chelonae-abscessus
group showed a higher increase in cases number followed by M. fortuitum and M.
avium. (Donohue 2018)
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Infections caused by the M. abscessus complex are currently treated mainly with
intravenous aminoglycosides+beta-lactam antibiotics and toxic drug combinations. Indeed,
intravenous amikacin is considered the most activity antibiotic currently available against
infections caused by M. abscessus. Most of the oral antibiotics tested in vitro does not show
any activity against this organism. Macrolides are oral antibiotics efficient against NTM,
however their efficiency depends on the genetic variations in the subspecies, which
generates variable response to the drugs.
The drug pipeline for treatment of drug resistant and opportunistic pathogens has to
keep growing and continuous efforts and initiatives are needed. To explore novel and new
targets is essential for the design and discovery of new drugs. In fact, an attractive target
for drug discovery against bacterial agents and cancer cells are topoisomerases; these
enzymes have been known as drug targets for about 45 years (Bush, Evans-Roberts et al.
2015) and compounds targeting certain types of topoisomerases are available.
In bacteria, drugs targeting type II topoisomerases are currently used as well as
anticancer drugs targeting type IB topoisomerases. For instance, fluoroquinolones
(ciprofloxacin, norfloxacin, levofloxacin, moxifloxacin) (Drlica and Malik 2003), potent
antimicrobial agents for treatment of infections caused by gram-positives, gram-negatives
and mycobacteria target DNA gyrase and generates cell death by creating toxic DNA
gyrase-DNA covalent intermediates (poison inhibitors).

On the other hand,

Aminocoumarins (Novobiocin, clorobiocin, coumermycin A1) are antimicrobial agents
targeting DNA gyrase and type IV topoisomerase, but they inhibit the first step in
topoisomerases function, DNA cleavage, then there is not formation of covalent
intermediate. These compounds are classified as catalytic inhibitors (Heide 2009, Heide
2014, Mayer and Janin 2014).

7

Compounds like etoposide and doxorubicin target type II topoisomerases in human
cells (Nitiss 2002) while camptothecin derivates: topotecan and irinotecan, target type IB
topoisomerases. Camptothecin-derived drugs are clinically accepted for cancer treatment
and show less adverse side effects compared to the camptothecin, used in the past (Martino,
Della Volpe et al. 2017). Both classes of human topoisomerase inhibitors, type II and type
IB topoisomerase inhibitors, are classified as poison inhibitors (Pommier 2013). However,
no drugs targeting bacterial or human type IA topoisomerases have yet been discovered
(Figure 8).

Why are topoisomerases relevant as drug targets?
Topoisomerases are enzymes present in all living organisms. These enzymes solve all
topological problems that are related to the physical structure of the double helix of the
DNA and influence the DNA replication, transcription, recombination and DNA repair
(Wang 2002, Viard and de la Tour 2007, Chen, Chan et al. 2013). Structurally, the DNA
is a right-handed double helix strand with constrained ends that because its extension
cannot be kept as an open structure in the cell. In eukaryotic organisms, the double helix is
condensed around histones, small basic proteins H2A, H2B, H3, H4 (11 to 15 kDa) that
form octamers; the resulting structure is called a nucleosome. Each nucleosome condenses
147 DNA base pairs around the protein octamer. Nucleosomes are packed together to
create chromatin. Moreover, nucleosomes are connected by short regions of naked DNA
(20 to 90 base pairs) named linkers, see

Figure 3 (Kouzine, Levens et al. 2014).

8

Figure 3. Structural conformation of chromatin in eukaryotic cells
The double stranded DNA is wrapped around a tetramer of histone proteins forming
the nucleosomes. Several nucleosomes form the chromatin and two chromatins are
part of a chromosome.
https://www.creative-diagnostics.com/blog/index.php/what-are-histones/

In prokaryotic organisms, specifically eubacteria, the DNA molecule is associated
with proteins such as: HU (heat-unstable), H-NS (heat-stable or histone-like nucleoidstructuring), Dps (DNA-binding protein from starved cells), FIS (factor for inversion
stimulation) and IHF (integration host factor), which all together form the nucleoid
structure analogue of nucleus in eukaryotic cells (Travers and Muskhelishvili 2005). A
published model for DNA condensation in bacteria establishes that H-NS protein binds to
DNA through its DNA binding domains and the proximity with other DNA duplexes
facilitate the formation of bridges between DNA molecules.

Hence, additional

condensation is generated by oligomerization of H-NS molecules (Figure 4) (Dame,
Wyman et al. 2000).

9

Figure 4. Model of DNA condensation by H-NS protein in the bacterial nucleoid.
H-NS proteins (small ovals), form dimers or tetramers that have at least two DNA
binding sites. A H-NS protein binds to a DNA strand and the proximity of another DNA
strand lead the formation of intramolecular interaction. Further oligomerization of
lateral H-NS proteins generates another level of compaction. (Dame, Wyman et al.
2000)
Packing and condensation of DNA in eukaryotic and prokaryotic organisms creates
DNA entanglements that require continuous conformational changes due to dynamic
nature of the chromatin. Topoisomerases are essential to maintain the topology stability
resolving DNA entanglements. Wrapping DNA around histones in eukaryotic cells or other
proteins in prokaryotic cells, creates positive or negative supercoils; positive if the DNA is
twisted in the same direction as the helix and negative when the DNA is twisted in the
opposite direction. Other factors playing a role in the supercoiling are the bending of the
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DNA helix in space to form higher structures, unwinding or rewinding of DNA duplexes
and chromatin remodeling (Chen, Chan et al. 2013, Gilbert and Allan 2014). All these
phenomena generate supercoiling domains whose structures must have barriers to prevent
topological stress produced by activities in neighbor domains and genes. The double helix
DNA is separated permanently or temporary for activities such as replication, transcription
and recombination. A very clear example of temporary separation of DNA is the twin
supercoiled domain model (Liu and Wang 1987). The model described that during
transcription the RNA polymerase has to rotate around the DNA strand to be transcribed,
however a resistance to the rotation could be presented and as consequence the DNA has
to rotate as well generating positive supercoiling ahead and negative supercoiling behind.
RNA polymerase stalling because of torsional stress (Ma and Wang 2014), promote
transcription of upstream genes (negative supercoiled DNA) or prevent the transcription of
downstream genes (positive supercoiled DNA) (Gartenberg and Wang 1992, Revyakin,
Ebright et al. 2004). The negative supercoiling can promote transcription by cooperation
in the recruitment of transcription factors in eukaryotic cells (Tabuchi, Handa et al. 1993)
or by helping RNA polymerase to form an open complex in prokaryotic cells. In regard to
the effects of positive supercoiling in downstream genes, transcription initiation can be
inhibited (Revyakin, Ebright et al. 2004) or the mRNA production be reduced (Gartenberg
and Wang 1992). According to the cell needs, all this supercoiling tension must be relaxed
to avoid undesirable outcomes. Type IA and IB topoisomerases are involved in the removal
of negative supercoiling generated upstream the transcription bubble; this prevents
additional gene transcription. Two compounds, Top IB and Top II are important in the
relaxation of positive supercoils ahead. Top IB is important specially in eukaryotic cells
and Top IV and gyrase in prokaryotic organisms (Figure 5) (Vos, Tretter et al. 2011).
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Permanent separation of DNA occurs during replication and hence accumulation of
precatenanes upstream the replication fork and positive supercoils downstream (Figure 6)
(Vos, Tretter et al. 2011) . In bacteria DNA gyrase is needed to relax the positive
supercoiling ahead and Top IV is more associated to the unlinking of the precatenanes, but
also can relax positive supercoils (Deweese and Osheroff 2009) .

Figure 5. Topological stress during DNA transcription and topoisomerases functions.
As the transcription bubble progresses, negative supercoils are left behind and positive
supercoils ahead. The enzymes listed in the figure are responsible to resolve the DNA
stress (Vos, Tretter et al. 2011)
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Figure 6. Topological stress during DNA replication and topoisomerases functions.
Replisome progression generate positive supercoils ahead, which need to be removed
to prevent premature termination of DNA replication. Additionally, the precatenanes
behind the replisome can lead to DNA catenation and further abnormal DNA
segregation during cellular division. (Vos, Tretter et al. 2011)

According to the previous description about the important function of topoisomerases in
DNA stability, the efforts for the development of drugs targeting these enzymes as well as
the efficacy of current drugs targeting them are understandable.
Classification of Topoisomerases
Topoisomerases are classified primarily according to structure and mechanism into two
types: Type I and II Topoisomerases. Type I topoisomerases are monomeric enzymes that
cleave only one strand (single strand) of DNA. Type II topoisomerases can be
heterotetrameric or homodimeric and cleave both strands (duplex) (Figure 7) (Champoux
2001) .
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Figure 7. Type I and type II topoisomerases
A) Type I topoisomerase breaks only one DNA strand allowing the passage through
the break or rotation of the intact single strand to change the DNA linking number. B)
Type II topoisomerase generate a double DNA breakage and passage of the intact
duplex DNA through the breakage.
http://www.lookfordiagnosis.com/mesh_info.php?term=dna+topoisomerases%2C+ty
pe+i&lang=1

Type I topoisomerases are subdivided in top A and top B on the basis of polarity. All
the topoisomerases contain a conserved tyrosine residue in their active site, the hydroxyl
group from the tyrosine is responsible for a transesterification reaction either with the 5'phosphate of the DNA in case of type IA and IIA topoisomerases or with the 3'- phosphate
in case of type IB topoisomerase (Figure 8) (Pommier 2013). The phosphotyrosyl transient
covalent bond generates a DNA breakage allowing the passing through of the intact DNA
strand in type IA topoisomerase. In type IB topoisomerases the mechanism is different; the
broken 5'-end rotate around the intact DNA strand. In type IIA topoisomerase the double
DNA breakage allow the passing through of a duplex DNA for relaxing positive
supercoiling or decatenation processes (Figure 9) (Pommier 2013). In Figure 10 the
transient phosphotyrosyl covalent bond for type IA topoisomerase is schematized; the
hydroxyl group from the tyrosine act as a nucleophile, attacking the 5'-phosphate in the
DNA leaving a 3'-hydroxyl free group on the broken DNA strand (Viard and de la Tour
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2007). When the strand passage is complete the 3'-hydroxyl free group on the DNA acts
now as the nucleophile attacking the covalent binding DNA-topoisomerase to rejoin the
DNA and finishing the process.

Figure 8. Classification of Topoisomerases
Type IA and IIA topoisomerases generates a 5’-phosphotyrosine bond when break the
DNA while the type IB generates a 3’-phosphotyrosine bond. Type IB topoisomerases are
found mainly in eukaryotic cells while type IA and IIA are found in prokaryotes as well.
No drugs targeting type IA have yet been discovered.(Pommier 2013)
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Figure 9. Catalytic mechanism of topoisomerases
A) type IA topoisomerase breaks a single DNA strand creating a 5’-phosphotyrosine
end, the intact strand pass through the breakage. B) type IB topoisomerase breaks a
single DNA strand creating a 3’-phosphotyrosine end. C) type IA topoisomerase breaks
both strands in the DNA duplex and create two 5’-phosphotyrosine ends, the intact
DNA duplex then pass through the breakage.(Pommier 2013)
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Figure 10. Transient phosphotyrosyl covalent bond in type IA topoisomerase
Active site of the topoisomerase IA showing the tyrosine responsible for the DNA
breakage. The hydroxy group from the tyrosine creates a covalent intermediate with the
5’-DNA phosphate. The covalent bound is reversible, resealing the DNA breakage.
(Viard and de la Tour 2007)

Topoisomerase IA in bacteria
All bacteria species contain at least two genes coding for topoisomerases, a type IA
topoisomerase and a type IIA topoisomerase (DNA gyrase) (Forterre and Gadelle 2009).
As stated previously in the present document, drugs targeting DNA gyrase are currently in
use but not drugs targeting topoisomerase IA have yet been discovered. Structural and
mechanistic information for the enzyme, as well as high-throughput screening of
compound libraries, are fundamental for the design and discovery of drugs targeting the
enzyme.
Most of the knowledge about type IA topoisomerase comes from E. coli topoisomerase
I and III. E. coli type IA topoisomerase. However, the recent elucidation of M. tuberculosis
topoisomerase IA has generated valuable information, which will be useful to study the
potential that this enzyme has as a drug target.
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E. coli topoisomerase IA is a monomeric protein with three main domains: N-terminal
(67 kDa) domain, zinc binding domain and C-terminal binding domain (14 kDa). The Nterminal domain contains four subdomains known as D1-D4 (Figure 11); this region
contains the active residues on the D1 and D3 subdomains: D111, D113 Y319 and R321.

Figure 11. E. coli type IA topoisomerase structure binding a ssDNA: N-terminal (TOP67)
and C-terminal domains (TOP30C).
A) Domain arrangement in E. coli topoisomerase IA B) Structure of full-length E. coli
topoisomerase IA with the ssDNA bound to the C-terminal domain (D5-D9
subdomains) and Zinc (II) ions. D1-D4 subdomains form the N-terminal domain, (Tan,
Zhou et al. 2015).
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The Y319 residue on D3 is responsible for the breakage of the G-strand from the
ssDNA and formation of the covalent intermediate. The R321 residue has been shown also
to be important for DNA cleavage, since it helps to keep the DNA in position (Tan, Zhou
et al. 2015). Additionally, the TOPRIM is a conserved motif in the catalytic core, which
contains two aspartate and one glutamate residue DDE (Figure 12). Because of their
chemical nature, these acidic residues have been associated with binding of metal ions,
such as Mg2+ in the catalytic core. For E. coli type IA topoisomerase, the TOPRIM residues
correspond to E9, D111 and D113 (Sissi and Palumbo 2009, Zhang, Cheng et al. 2011). In
general, the active site on the N-terminal domain of type IA topoisomerases is conserved
among domains of life since this region hold the DNA cleavage and religation activities,
primary functions of this group of enzymes (Banda, Cao et al. 2017, Capranico, Marinello
et al. 2017).
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Figure 12. Residues in active site of E. coli type IA topoisomerase.
Two residues, D111 and D113 part of the conserved TOPRIM domain are shown as
well as the tyrosine responsible for the nucleophilic attack to the 5’-phosphate on the
DNA strand (Tan, Zhou et al. 2015).
The D1, D2, D3 and D4 domains in M. tuberculosis are similar to E. coli topoisomerase
IA, their sequence identity corresponds to 56%, 26.9%, 49.6% and 49.2%, respectively
(Figure 13). The D1 domain is the most conserved between these enzymes and it is also
known as TOPRIM domain (Tan, Cao et al. 2016). The superposition of these two Nterminal domain structures reveals a very similar conformation. The D1 domain have been
found also to be conserved among other species.
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Figure 13. M. tuberculosis topoisomerase IA 740t structure.
N-terminal domain is formed by D1, D2, DE and D4 domains. The grey protrusion in
D1 is considered part of D4 domain. In D2 there are two loop conformations colored
magenta and red. The D3 domain contains the Y342 (catalytic residue) and in D4 there
is an uncommon insertion colored purple. D5 domain is part of the C-terminal domain
(Tan, Cao et al. 2016).
Unlike the N-terminal domain, the C-terminal domain in Topoisomerase IA from
different species is more diverse. The C-terminal domain of E. coli topoisomerase IA
contains a 4-Cys zinc ribbon domain (D5-D7) and two zinc ribbon like domain (D8-D9).
The C-terminal domain is important in the primary interaction with the ssDNA, specially
D5 and followed by D7, D8, D9. The four conserved cysteines on the 4-Cys zinc ribbon
domain (D5-D7) coordinates Zn (III) ions while the two-zinc ribbon like domain (D8-D9)
do not have Zn-binding site. The number of zinc bindings motifs are variable among
species. The C-terminal subdomain D6 interacts with the N-terminal subdomain D2 and
D4, which may be important in the regulation of the enzyme activity. In Figure 14, the
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structure of E. coli topoisomerase IA schematizes two models that describe interactions
with the DNA. On the left, the C-terminal domain interacts with the G-strand in ssDNA
and on the right interacts with the T-strand in dsDNA.

Figure 14. DNA-E. coli topoisomerase IA interaction
Two models of E. coli topoisomerase IA-DNA binding. On the left, B) Topoisomerase
IA binds to a single chain of ssDNA. In this model the ssDNA G-strand interacts with
the N-terminal and C-terminal domains. On the right side, C) The double chain model
shows that the T-strand binds to the C-terminal domain while the G-strand binds to the
N-terminal domain. In this model the D6 domain may act as a handle that push or pull
the hinge between D2 and D4 that regulates the gate opening. (Tan, Zhou et al. 2015).

The C-terminal domain in M. tuberculosis topoisomerase IA is divided into four
regions known as D5, D6, D7 and D8. No D9 subdomain is present, instead a positively
charge tail is the last region of the enzyme. The subdomains are separated according to the
location of four different repeats GxxGPY. Moreover, the C-terminal domain in M.
tuberculosis topoisomerase IA and other mycobacteria species does not have zinc finger
motifs, but the presence of three basic amino-acid stretches provides insights to their

22

relevance in DNA binding and relaxation activity (Ahmed, Bhat et al. 2013). In fact, it has
been shown that these basic amino-acid stretches are indispensable for strand passage
during DNA relaxation activity and the absence of them do not affect enzyme mechanisms
such as DNA cleavage and rejoining (Figure 15).

Figure 15. Basic amino acids stretches in C-terminal domain of Mycobacteria
topoisomerase IA
Basic amino acids stretches highlighted in Multiple alignment of C-terminal domain
Topoisomerase IA from diverse Mycobacteria species. M. tuberculosis (Mt), M. bovis
(Mb), M. leprae (Ml), M.avium (Ma), M. avium subsp. paratuberculosis (Ma(ptb)), M.
smegmatis (Ms). (Ahmed, Bhat et al. 2013)

The topoisomerases’ interactions with natural partners have been also subject of study
to understand the inhibition, regulation and cooperation processes associated with these
enzymes. The C-terminal domain from E.coli and M. tuberculosis topoisomerase IA for
example, interacts with RNA polymerase, the β’ subunit to be exact, in a cooperative effort
to relax the hyper negative supercoiled DNA behind the transcription bubble (Cheng, Zhu
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et al. 2003, Tiwari, Chapagain et al. 2016, Banda, Cao et al. 2017). Additionally, the
interaction between a helicase like domain and topoisomerase IA is important to positively
supercoil DNA maintaining its duplex structure (Viard and de la Tour 2007). There are
interactions that negatively affect the topoisomerase IA activity such as toxin-antitoxin
systems, whose toxin has the ability to deplete the topoisomerase activity under certain
conditions. Diversity among C-terminal domains from different organisms and the
existence of molecules that interact in vivo with this region for regulatory or functional
purposes is an opportunity for the discovery of selective drugs.

Topoisomerase IA is essential in Mycobacteria
M. tuberculosis genome encodes only one copy of type I topoisomerase and one copy
of type II topoisomerase (DNA gyrase). Growth and survival experiments in M.
tuberculosis and M. smegmatis strains have shown that depletion in topoisomerase IA
levels generate impairment not only in growth but also in cell survival (Figure 16). These
results generate insights about the potential of Topoisomerase IA as a target in M.
tuberculosis and NTM. In fact, anticancer drugs candidates and old antimicrobial agents
are being repurposed as antimycobacterial agents and some of them have been found to be
active against mycobacterial topoisomerase IA.
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Synopsys
Novel and alternative antimicrobial agents as well as new targets are matters that must
be addressed in the continuous battle against infectious diseases. M. tuberculosis is a
declared public health problem worldwide and NTM are emerging as frequent human
pathogens, several publications are exposing the increased incidence of these infections
around the world: Netherlands, United States, Japan, South Korea, Taiwan are some of the
countries reporting increase in NTM associated infections.
In the dissertation project, two perspectives in the fight against infectious diseases are
addressed, firstly, a novel and a repurposed antimicrobial agent are subject of study as
potential drugs for treatment of infections caused by Mycobacteria. Furthermore, study of
the interaction of Mtop IA with the MazF toxin in M. tuberculosis bring out insights about
the relevance of the C-terminal domain in Mtop IA for the design of specific antimicrobial
agents effective in TB treatment.
In CHAPTER 2, Ethacridine, an FDA approved antimicrobial agent is brought out as
an alternative for TB treatment because of its activity against M. tuberculosis and Mtop IA.
The mechanisms of drug resistance to this drug as well as its combinatory effect with a
currently used drug for TB treatment, Moxifloxacin.
In CHAPTER 3, a novel compound, FP-11g, with promising activity against M.
tuberculosis is evaluated against M. abscessus as wells as the mechanism of drug resistance
to this drug.
In CHAPTER 4, the ability of a M. tuberculosis toxin, MazF, to inhibit Mtop IA
function in vitro is evaluated to identify the Mtop IA region responsible for this interaction.
To elucidate this interaction is relevant for future design of drugs targeting specifically
MtopIA.

26

2. Mtop IA inhibition by RV1495 as a model for drug discovery
Background information
M. tuberculosis is a microorganism able to persist in the host for a long time through
granuloma formation, however the molecular bases are not very well understood. Stress
responsive Toxin-Antitoxin (TA) systems have been proposed as mediators of granuloma
formation in M. tuberculosis since in other bacterial species (e.g., E. coli) TA systems are
known to generate persisters. M. tuberculosis has a high number of TA systems compared
to other mycobacteria (Figure 17), this could be associated with its virulence and latent
infection (Sala, Bordes et al. 2014). In fact, TA systems up-regulation during antibiotic
treatment has been reported in M. tuberculosiss (Keren, Minami et al. 2011). Under stress
conditions the antitoxins are degraded and the free toxins can target important cellular
processes like replication and transcription that finally would inhibit the protein expression
and cell growth to induce latency and facilitate cellular survival until the conditions become
favorable (Sala, Bordes et al. 2014).

Figure 17. Toxin-antitoxin systems in Mycobacteria
Toxin- antitoxin information collected from TADB (toxin-antitoxin database), NCBI
and BLASTP. In M. smegmatis the TAC system is incomplete and some toxin-antitoxin
systems could not be classified. (Sala, Bordes et al. 2014)
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The toxin Rv1495 belongs to the MazEF family (MazE is the antitoxin and MazF is
the toxin), which include mainly endoribonucleases and in certain cases target ribosomal
RNA (Zhu, Phadtare et al. 2008). Recent studies have shown that besides being an
endoribonuclease, The Rv1495 toxin (MazF homolog in M. tuberculosis) interacts with
DNA topoisomerase I and they mutually inhibit each other (Figure 18), (Huang and He
2010). The physical interaction between Rv1495 and MtopI/ M. smegmatis topoisomerase
I has been demonstrated through bacterial two-hybrid assay and biochemical assays such
as pull-down in the previous study. The functional inhibition of MtopI/ M. smegmatis
topoisomerase I by Rv1495 was established through a DNA relaxation assay and singlestranded DNA cleavage assay by the same group. The DNA relaxation assay showed that
increasing concentrations of the purified Rv1495 toxin generates a reduction of the Mtop I
DNA relaxation efficiency (Figure 19). The cleavage capacity of MtopI on ssDNA was
also compromised as shown in (Figure 20), with the presence of increasing concentrations
of Rv1495 decreases the amount of ssDNA cleavage product.
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Figure 18. MazF-MazE Toxin-antitoxin system
Under normal conditions the antitoxin prevents the toxin activation by forming a
complex with it. When the cells are exposed to stress conditions, the toxin-antitoxin is
dissociated, and the antitoxin degraded. MazF toxin interacts with the mRNA and Mtop
IA to induce a latent stage that is important for cell survival in these conditions.

Figure 19. DNA relaxation activity of Mtop I in presence of increasing concentrations of
Rv1495
On the left-hand, the relaxation activity of Mtop IA is tested using different enzyme
concentrations 0.05, 0.10 and 0.15 μM. On the right hand, the relaxation activity of Mtop
IA (0.125 μM) is tested in presence of variable concentrations of Rv1495: 0, 1.5, 3, 4.5
and 6 μM. (Huang and He 2010)
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Figure 20. DNA cleavage activity of MtopI in presence of increasing concentrations of
Rv1495
On the left-hand, the ssDNA cleavage activity of Mtop IA is tested using different
enzyme concentrations 0.1, 0.2, 0.3 and 0.4 μM. On the right hand, the cleavage activity
of Mtop IA (0.2 μM) is tested in presence of variable concentrations of Rv1495: 3, 6
and 6 μM. (Huang and He 2010)

Additional information provided by this study also demonstrated that Rv1495 interacts
with the C-terminal domain of Mtop I. The mRNA cleavage activity of Rv1495 was tested
in presence of the MtopI N-terminal domain and C-terminal domain separately. As shown
in Figure 21, when the concentration of the C-terminal domain is increased the capacity of
Rv1495 to cleavage the mRNA substrate is decreased.
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Figure 21. mRNA cleavage activity of Rv1495 in presence of Mtop I N-terminal and Cterminal domain
The mRNA cleavage of Rv1495 (0.6 μM) is tested in presence of diverse concentrations
of Mtop IA N-terminal and C-terminal domain: 0.1, 0.2 and 0.3 μM. ( (Huang and He
2010)
In the current project we followed up the findings on Rv1495-Mtop IA interaction to
try to generate detailed information about the specific region on MtopI C-terminal domain
that is responsible for the interaction with the Rv1495 toxin.

Research objectives
To study the Rv1495-Mtop I interaction, as a potential model for the identification of
antitubercular compounds that target Mtop I C-terminal domain
•

To establish a screening assay for the inhibition of Mtop I by Rv1495 toxin

•

To identify the critical amino acids and/or subdomain on Mtop I C-terminal domain
responsible for its interaction with Rv1495

•

Protein expression and purification of Rv1495 toxin for identification of binding
site by crystallography. This will enable design of small molecule Top I inhibitor
selective for Mycobacteria.
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Material and Methods
Preparation of E. coli AS17 Electrocompetent cells
A 250 ml volume of LBN (Luria-Bertani broth with 0.16 M NaCl) media was
inoculated with 2.5 ml of cells from overnight culture and incubated at 30°C with shaking.
When cells reached exponential phase (O.D.600nm =0.4-0.8), the whole cell volume was
spun down in five 50 ml tubes at 3600xg and 4°C for 10 min. All the pellets were
resuspended in 50 ml of 10% glycerol and spun down at the same conditions. The same
procedure was repeated four more times. Finally, the pellet was resuspended in 800 μL of
10% glycerol. Aliquots of 60 μL were stored in 1.5 ml tubes and stored at -80°C.

Preparation of E. coli NEB-5 chemically competent cells
The E. coli NEB-5 cells fhuA2a(argF-lacZ)U169 phoA glnV44 a80a(lacZ)M15 gyrA96
recA1 relA1 endA1 thi-1 hsdR17 were growth following the same protocol for
electrocompetent cells preparation. The total volume inoculated was 50 ml and when the
cells reached exponential phase, the whole culture was spun down and the supernatant
discarded. The pellet was resuspended in 5 ml of TSS buffer (LB broth containing 0.1 g/ml
PEG8000, 5% DMSO, 30 mM MgCl2). Aliquots of 100 μL of the competent cells were
stored in 1.5 ml tubes at -80°C.

Transformation of chemically competent cells
The plasmid DNA was added to a 60 μL or 0.1 ml aliquot of competent cells and
incubated on ice for 30 min, afterwards the cells-DNA mix was exposed to heat shock in a
water bath at 42 °C for exactly 45 second and immediately removed to place it on ice. The
tube was left on ice for 2 min and then 0.9 ml of SOC medium added for cell recovery.
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Cells were incubated shaking at 37 °C for 1 hour before aliquots were spread on LB plates
with antibiotics for plasmid selection.

Transformation of electrocompetent cells
The 0.1 cm cuvettes and cuvettes holder were pre-chilled at -20 °C and the
electrocompetent cells thawed on ice for 5 minutes. One microliter of plasmid DNA was
added to 60 μL of competent cells. The mixture was transferred to a cold electroporation
cuvette, which was placed into the electroporator chamber slide. The micropulse was set
to EC1 bacteria and the slide pushed into the chamber until the cuvette was in between the
electrodes on the base of the chamber. The pulse bottom was pressed until hearing a beep,
immediately the cuvette was removed from the chamber and 950 μL of SOC medium added
to the cuvette. The cell suspension was transferred to a 14 ml tube and shaken at 30°C for
1.5 hours before plating.

Complementation assays of E. coli AS17 cells with full length Mtop I and EtopI
in the presence and absence of the Rv1495 toxin
Escherichia coli topAts strains AS17 (Wang, Lynch et al. 2002) were used to test the
specific inhibition of Mtop I by Rv1495 toxin. AS17 cells contain a topA allele coding for
topoisomerase I that is thermosensitive. Under permissive temperature (30 °C) AS17 cells
grow, but not at the same level as WT cells. On the other hand, when these cells are exposed
to non-permissive temperature (42°C), the TopA activity is considerably reduced and the
cells are not able to grow. In our lab, AS17 cells which contain the pLIC plasmid
expressing either E. coli topoisomerase I (EtopI) or Mtop I, which complement the
thermosensitve TopA at 42 °C, are used for testing intraceullar inhibition of these
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topoisomerase IA (Figure 22a). The AS17 cells containing pLIC vector, pLICEtop I or
pLICMtop I were transformed with an additional plasmid expressing Rv1495 toxin (Figure
22b). All the transformants were tested through complementation assays at 30 and 42°C in
order to evaluate the Rv1495 inhibitory effect on topoisomerase I function (Figure 22c).
For complementation assays, the cells were grown overnight at 30oC in LBN broth in
presence of kanamycin (50 μg/ml) and carbenicillin (100 μg/ml), afterwards the O.D was
adjusted to 1.0 and serial dilutions done with LBN broth in a 96 well plate. Five microliters
of serially diluted cells were spotted in LBN plates (kanamycin 50 μg/ml and carbenicillin
100 μg/ml) containing 0.2% arabinose 0.2% to induce the expression of the Rv1495 toxin.
Differences in cell growth confirmed the inhibition of Mtop I by Rv1495 toxin. (IBC-16009-CR02).
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Figure 22. Complementation of E. coli AS17 cells (thermo-sensitive Topoisomerase I)
by recombinant topoisomerase I
A.) E. coli topAts strain AS17 containing pLICMtop IA plasmid, which complements
the cell growth at 42°C. B.) E. coli topAts strains AS17 containing pLICMtop IA and
pBAD-Rv1495. Presence of Rv1495 in the E. coli AS17 cells reverse the growth
complementation produced by Mtop IA. C.) On top, serial dilutions of E. coli topAts
strains AS17 incubated at 30°C and 42°C. In the bottom, serial dilutions of E. coli topAts
strains AS17 containing pLICMtop IA incubated at 30°C and 42°C.
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Random mutagenesis of pLICMtop I plasmid
The Rv1495 toxin inhibits MtopI activity through its interaction with the MtopI CTD
(Huang and He 2010). We created a random mutant library of Mtop I using Escherichia
coli XL-1 Red cells endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac mutD5 mutS mutT Tn10
(Tetr) (Agilent technologies Catalog #200129), a strain deficient in three DNA repair
pathways. pLICMtop I WT plasmid was transformed into XL-1 Red chemically competent
cells (two transformations were performed at the same time). The transformed cells (0.9
ml of SOC) were separated in two aliquots (0.45 ml each) and spun down, 0.2 ml of
supernatant removed, and pellets were resuspended in the remaining 0.2 ml for plating on
four LBN kanamycin (50 μg/ml) agar plates for incubation at 37°C. After overnight
incubation, all the isolated transformants (more than 200 cfu per plate) from the four plates
were transferred to 100 ml of LBN kanamycin (50 μg/ml) and cultured overnight with
shaking at 37°C. A second cycle of growth for the XL1 Red transformants was performed
in order to increases the mutation rate in pLICMtopI plasmid, Five ml from the 100 ml
culture was used to inoculate fresh 200 ml of LBN kanamyci (50 μg/ml) broth and
incubated with shaking at 37 °C. Five ml from the first and second cycle cultures were
spun down for plasmid preparation using Monarch® Plasmid Miniprep kit. After plasmid
preparation, the random libraries preparations were pooled together for further
transformation of competent XL-1 Blue cells to prepare library stock.
The XL-1 Blue cells recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F ́proAB
lacIqZΔM15 Tn10 (Tetr)] (Agilent technologies Catalog #200236) are the maintenance
cells used for storage of our mutant’s libraries. Fifty nanograms of pLICMtop I mutant
library DNA from XL-1 Red cells was used for transformation of XL-1 Blue cells using
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the chemically competent cells transformation protocol. Monarch® Plasmid Miniprep kit
was used for XL1-Blue cells plasmid preparation (Figure 23).

Isolation of Mtop I mutant gene from pLIC Mtop I random mutant plasmid
library
The NEBcutter V2.0 online tool was used to identify unique restriction sites that
allowed the linearization of Mtop I gene fraction from the plasmid. pLICMtop I mutant
library from XL-1 Blue cells. The plasmid was double digested with BamHI-HF® and
NcoI-HF® from NEB: 1 μg of plasmid DNA was mix with 5 μl of 10X CutSmart Buffer
and 1 μl (or 10 units) of each enzyme. The reaction was incubated at 37 °C for 15 minutes.
Digested product was electrophoresed in a DNA agarose 1% gel for DNA separation and
cutting of the gel band containing mutated MtopI. The band of interest was cut and DNA
was purified from the gel using Monarch® DNA Gel Extraction Kit from NEB (Figure 23).

Isolation of pLIC WT vector from pLIC Mtop I WT plasmid
The pLIC WT vector backbone was isolated from the pLICMtop I WT plasmid (no
pre-treatment in XL-1 Red cells) through enzyme digestion using the BamHI-HF® and
NcoI-HF® from NEB and following the protocol already described for the isolation of
Mtop I mutant gene (Figure 23).
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Ligation of linearized bands (pLIC WT and Mtop I mutant library) for
creation of Mtop I random mutant library
The NEBioCalculator v1.8.1 tool was used to set up the ligation reaction according to
the size of the vector (5271 bp) and insert (2881 bp). In total, 1 μl of pLIC WT linearized
vector backbone (concentration: 40.2 ng/μl) and 2 μl of Mtop I linearized gene (45 ng/μl)
from the mutant library were added to the ligation reaction, which also contained 2 μl of
10X T4 DNA ligase buffer, 14 μl of nuclease free water and 1 μl of T4 DNA ligase. The
reaction was incubated overnight (14 h approximately) at 16°C in a thermocycler and then
inactivated in a water bath heater at 65°C for 10 minutes.
The XL-1 Blue competent cells were transformed with the ligation product for MtopI
mutant library generation. Two transformations of 0.1 ml XL-1 Blue cells were performed,
5 μl of ligation product was used for each transformation. The same protocol as for XL-1
Red competent cells was performed. Recovered cells were plated in LBN agar (kanamycin
50 μg/ml); 0.15 ml was spread on each plate (total volume 0.9 ml). After colonies
formation, 1 ml of fresh LBN broth (kanamycin 50 μg/ml) was added to each plate
containing 60 μl the colonies and the cells (more than 500 cfu per plate) collected in a 15
ml tube. Plasmid preparation of the mutant library was done using Monarch® DNA Gel
Extraction Kit from NEB (Figure 23).
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E. coli AS17
XL1 Red cells

XL1 Red cells

pLIC Mtop I WT

pLIC Mtop I
Mutant

pLIC Mtop I WT

XL1 Red cells
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Figure 23. Scheme for generating plasmid library with random mutations in Mtop I gene
XL-1 Red cells is transformed with pLICMtop IA plasmid for insertion of random mutants throughout the plasmid. The mutant
pLICMtop IA plasmid is recovered from the XL1 Red cells and excises to obtain the Mtop IA mutant region only. Additionally, a WT
version of pLICMtop IA is excised to obtain the non-mutated pLIC region. Both fragments, Mtop IA mutant and non-mutated pLIC
vector are ligated and used for transformation of E. coli AS17 pBAD-Rv1495, which are selected at 42ºC for further studies and
sequencing if required.
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Selection of random mutant LICMtopI clone resistant to Rv1495 inhibition.
The E. coli AS17 pBAD-Rv1495 electrocompetent competent cells were transformed
with 50-100 ng of pLICMtop I mutant library. After recovery, 0.1 ml of cells were plated
in two LBN agar containing kanamycin (50 μg/ml), carbenicillin (100 μg/ml) and 0.2%
arabinose. One plate was incubated at 42ºC and the second one at 30ºC. Cells that are able
to grow at 42ºC were considered MtopI mutants resistant to Rv1495 inhibition. The
presence of arabinose in the plate induces the expression of the Rv1495 toxin from the
BAD promoter. Rv1495 interacts with MtopI WT and inhibits the enzyme activity, hence
no colonies should be isolated at 42ºC. However, if mutations that affect the Rv1495-Mtop
I interaction are present on pLICMtopI, the inhibition is abolished and the mutant MtopI
transformants grow at 42ºC. pLICMtopI WT plasmid was used as control in the isolation
of MtopI mutants. E. coli AS17 pBAD-Rv1495 cells were transformed with the WT
version of LICMtop I and no colonies should grow at 42ºC. There is nevertheless some
LICMtop I WT background growth at 42ºC (probably due to selection of inactivating
mutations on Rv1495), all selected LICMtop I mutant plasmids before being considered as
true positives were submitted to an additional selection step. pLICMtop I mutant plasmid
DNA was extracted and retransformed in E. coli AS17 pBAD-Rv1495 and the ratio of
number of transformants obtained at 42/30oC was compared to the LICMtop I WT
transformation. When the 42/30oC ratio of transformants obtained from pLICMtopI was
much greater than the WT pLICMtopI, the mutant pLICMtopI plasmid was considerate
true positive and sent for DNA sequencing (Figure 23).
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Cloning of truncated versions of MtopI-840t and 910t in pLIC vector.
MtopI-840t
Generation of two truncated versions of Mtop I in pLIC vector were performed through
Gibson cloning: for 840t cloning pLIC Forward CCGAATTCGAGCGCCGTCG and pLIC
Reverse TTTCATGGTGATGGTGATGGTG primers were used to obtain linearized and
truncated pLIC vector from pLICMtopI WT plasmid.
ccatcaccatcaccatgaaaACCTGTACTTCCAATCCAATGCA

The MtopI Forward
and

MtopI

Reverse

tcgacggcgctcgaattcggATCCGTTATCCACTTCCAATG primers were used to obtain
linearized LICMtopI-840t truncated clone from 2OT/MtopI-840t plasmid (an ampicillin
resistant clone constructed in 2OT cloning vector for earlier studies of Nan Cao in our lab).
The PCR conditions for the vector amplification included an initial denaturation for 30
seconds at 98°C, followed by 35 cycles: denaturation for 10 seconds at 98°C, primer
annealing for 30 seconds at 66°C and extension for 2 minute 30 seconds at 72°C. The PCR
conditions for the Mtop I-840t gene amplification included an initial denaturation for 30
seconds at 98°C, followed by 35 cycles: denaturation for 10 seconds at 98°C, primer
annealing for 30 seconds at 72°C and extension for 1 minute 30 seconds at 72°C. The final
extension for both amplification protocols was held for 5 minutes at 72°C.

MtopI-910t
The pLIC Forward TAATAACATTGGAAGTGGATAACGGATCCGAATTCGAG
and pLIC Reverse TGCATTGGATTGGAAGTACAGGTTTTC primers were used to
obtain linearized pLIC vector from pLICMtopI WT plasmid.
tgtacttccaatccaatgcaGCTGACCCGAAAACGAAGGG
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and

The MtopI Forward

MtopI

Reverse

primer

atccacttccaatgttattaCTAGGCTCGGCGATCGGC were used to create the MtopI-910t
truncated gene from pLICMtop I WT plasmid. The PCR conditions were similar to the
previously describe for MtopI-840t cloning, only the annealing temperatures were
modified: For vector amplification the annealing temperature was 68°C and for the insert
was 70°C.

Complementation assay measuring 42/30oC ratio of E. coli AS17
transformants with truncated versions of Mtop I in the presence and absence of
the Rv1495 toxin
The same protocol already described for MtopI full length complementation assay was
followed with the truncated versions of Mtop I: Mtop I-840t and Mtop I-910t. Additionally,
0.1 ml of serial dilutions were spread in LBN agar containing kanamycin (50 μg/ml),
carbenicillin (100 μg/ml) and 0.2% arabinose to obtain the exact colony counts and 42/30oC
ratio. The 42/30 oC ratio of E. coli AS17/pLICMtopI truncated clones vs. AS17/pLIC Mtop
I WT was compared in order to determine if the removed region of Mtop I is important for
Rv1495-Mtop I interaction.

Cloning of the Rv1495 toxin in pGEX-4T-3 vector
The Rv1495 toxin from M. tuberculosis was cloned through Gibson cloning in the
pGEX-4T-3 vector containing GST tag for expression and affinity purification. Primers
pGEX-4T-3

Forward,

AATTCCCGGGTCGACTCG

and

pGEX-4T-3

reverse

CGGGGATCCACGCGGAAC were used for the amplification/linearization of the vector.
The PCR conditions for the vector amplification included an initial denaturation for 30
seconds at 98°C, followed by 35 cycles: denaturation for 10 seconds at 98°C, primer
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annealing for 30 seconds at 68°C and extension for 2 minutes at 72°C. Final extension was
for 5 minutes at 72°C.
Primers Rv1495 Forward tggttccgcgtggatccccgGTGAACGCGCCGTTGCGT and
reverse

ctcgagtcgacccgggaattTCATGGCCACGGTAGCCC

were

used

for

the

amplification/linearization of the Rv1495 gene. The PCR conditions for the insert
amplification included an initial denaturation for 30 seconds at 98°C, followed by 35 cycles:
denaturation for 10 seconds at 98°C, primer annealing for 10 seconds at 72°C and extension
for 20 seconds at 72°C. Final extension was for 2 minutes at 72°C.
The size of PCR products was evaluated by electrophoresis in 1% agarose gel. From
the gel, the bands corresponding to the vector and insert were cut and DNA was purified
using the Zymoclean™ Gel DNA Recovery kit. The DNA concentrations for each purified
product (insert and vector) was quantified through UV spectrometry at A260 nm. For the
Gibson cloning reaction, the NEBuilder ® HiFi DNA Assembly Master Mix kit was used.
The number of picomoles of each fragment were first calculated based on their size:
linearized pGEX-4T-3 4968 bp, linearized Rv1495 gene 358bp, in order to combine them
in the proportions required for the Gibson cloning reaction. The reaction was incubated at
50°C for 10 min in a thermocycler. NEB® Turbo chemically competent E. coli cells were
transformed with the cloning product and selected in LBN plates containing carbenicillin
100 μg/ml. After plasmid preparation, transformants were selected and sent for DNA
sequencing to confirm Rv1495 sequence.
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Expression and purification of Rv1495 toxin
The E. coli BL21(DE3) chemically competent cells from Invitrogen were transformed
with the pGEX-4T3-Rv1495 plasmid for protein expression. Cells were cultured overnight
in 5 ml of LBN broth with carbenicillin 100 μg/ml at 37°C shaking. Next day, four 2L
flasks each of them with 500 ml of fresh 2x YT media (tryptone 16g, yeast extract 10g and
NaCl 5.0 g in 1L of water) with 100 μg/ml carbenicillin was inoculated with the overnight
culture (1:100 dilution) and incubated at 37°C shaking. When the cells reached exponential
phase O.D600nm 0.4- 0.8, IPTG (0.6 mM) was added and the cells were induced for 4 hours
at 37°C shaking. The induced cells were spun down, the supernatant removed and the
pellets kept on ice. Cell lysis was performed in PBS, pH 7.3 (300 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3) with lysozyme at final concentration of 1
mg/ml. The cell lysates were left on ice for 1 hour. Next, three cycles of freeze and thaw
were performed: for each cycle the sample was frozen at -80°C for 1 hour and thawed in
ice water for up to 2 hours. When the lysis is complete, a small fraction of the whole cell
lysate was collected to evaluate the protein expression and solubility. The remaining
soluble lysates were centrifugated at 32,000 rpm at 4°C for 2.5 hours and the supernatant
transferred to fresh tubes for further dilution with PBS buffer with 0mM NaCl in order to
reduce the salt concentration to 140 mM NaCl (the initial concentration for lysis purposes
was 300 mM). Fast protein liquid chromatography (FPLC) AKTA system and a 1 ml
prepacked GSTrapTM HP column from GE Healthcare were used for protein purification.
First, several system washes were performed with water and binding buffer (PBS, 140 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4,1.8 mM KH2PO4, pH 7.3). Afterwards, the column
was attached to the system and equilibrated with 5 ml of binding buffer (five column
volumes) with a flow rate of 0.1-0.2 ml/min. The sample was passed through the column
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at the same rate followed by extensive washing. The elution buffer (50 mM Tris-HCl, 10
mM reduced glutathione, pH 8.0) was applied to the column using flow rate of 0.5 ml/min.
Collected fractions were evaluated with SDS PAGE in 10% gels and the Bradford protein
assay. Fractions containing the Rv1495 fusion protein were pooled together for dialysis
into storage buffer (50% glycerol, 100 mM KH2PO4 , 0.2 M EDTA).

Results
Growth complementation assays of E. coli AS17 cells with full length Mtop I
and EtopI in the presence and absence of the Rv1495 toxin
The pLICEtop and pLICMtop complemented the growth of E. coli AS17 cells at 42ºC.
But when an additional plasmid pBAD-Rv1495 expressing the toxin was present in the cell,
complementation of growth by recombinant Mtop I was greatly reduced (Figure 24), while
EtopI still complemented the growth at the same level because the C-terminal domain of
EtopI shares no homology with MtopI C-terminal domain. The 42/30oC ratio for
AS17/pLICMtopI/pBADthio varies between 10-1 and 1, while for AS17/pLIC-Mtop
I/pBAD-Rv1495 the ratio varies between 10-5 and 10-3. In this first experiment we were
able to prove the specific inhibition of Mtop I by Rv1495 toxin.
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Figure 24. Growth complementation of E. coli AS17 with pLICMtopI and pLICEtop full
length
Serial dilution of E.coli AS17 cells were spotted on LBN agar plates (kanamycin 50 μg/ml
and carbenicillin 100 μg/ml) containing arabinose 0.2%. The plate was inoculated by
duplicate and incubated at 30ºC (on the left) and 42ºC (on the right). E.coli AS17 cells
containing either Etop I or Mtop IA showed growth complementation and the Rv1495 toxin
the specific inhibitory effect of Mtop IA by the toxin. 1).AS17/pLIC/pBADthio 2).
AS17/pLICEtop I/pBADthio 3). AS17/pLICMtop I/pBADthio 4). AS17/pLICEtop
I/pBADthio-Rv1495 5). AS17/pLICMtop I/pBAD-Rv1495
MtopI Random mutant selection and analysis
The pLICMtopI mutant library showed a higher 42/30oC transformation efficiency
ratio than pLICMtopI WT (Figure 25). Because of mutations generated on pLICMtopI in
XL-1 Red cells, the interaction between pLICMtopI and Rv1495 might be affected, which
would increase the number of transformants that can grow at 42ºC after transformation.
Eight isolates containing mutated pLICMtopI and that grew at 42ºC were selected for
plasmid preparation and further re-transformation of AS17/pBAD-Rv1495 to confirm that
resistance to Rv1495 inhibition.
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Figure 25. Mtop IA random mutant selection and 42/30 ºC ratio.
E.coli AS17 pBAD-Rv1495 cells were transformed either with pLICMtop I WT (left
panel) or pLICMtop I mutant library (right panel). The transformants were spread directly
(top) and diluted (bottom) on LBN agar plates (kanamycin 50 μg/ml and carbenicillin 100
μg/ml) containing arabinose 0.2%. Duplicates were spread for incubation at 42 ºC and 30
ºC. Diluted plates were used for cell counting and calculation of 42/30ºC ratio.
When AS17/pBAD-Rv1495 cells were re-transformed with purified mutant
pLICMtopI plasmids, pLICMtop mutant 3 showed a very high cell recovery at 42ºC
(Figure 26). Sequencing results did not reveal any mutations on MtopI coding region in
mutant 3. However Western Blot analysis showed that this mutant clone overexpressed
MtopI protein compared to an AS17/pBAD-Rv1495/pLICMtopI WT. The overexpression
of Mtop I in the mutant 3 confirms MtopI as the target for in vivo growth inhibition by
toxin Rv1495. The result also indicates that mutations that confer resistance to Rv1495 by
MtopI overexpression are likely to be less costly for cell growth compared to other
mutations in the MtopI coding sequence that may decrease growth complementation of
AS17 while conferring resistance to Rv1495.
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Figure 26. E.coli AS17 pBAD-Rv1495 cells re-transformation with pLICMtop mutant
library and Mtop IA expression.
A) E.coli AS17 pBAD-Rv1495 cells re-transformation with eight clones of pLICMtop I
mutant library selected at 42 ºC . Mutant 1, 2,4,5,6,7 and 8 showed comparable growth to
the pLICMtop I WT at 42 ºC.Mutant 3 showed a high recovery at 42 ºC (only mut 1 and
mut 3 are shown in the figure). B.) Western blot of Mtop IA in E.coli AS17 pBADRv1495/pLICMtop mutant 3 revealed overexpression of Mtop IA compared to the E.coli
AS17 pBAD-Rv1495/pLICMtop IA WT strain. 1). Purified Mtop I 2).Western blot MW
standards 3.) AS17/pBAD-Rv1495/pLICMtop WT 4). AS17/pBAD-Rv1495/pLICMtop
mut 3

Growth complementation assay of E. coli AS17 cells with truncated versions
of MtopI in the presence and absence of the Rv1495 toxin
The truncated versions of Mtop I designed for this study correspond to proteins with
C-terminal subdomain missing; for MtopI 840t, the subdomain D8 and the tail, and for
MtopI 910t only the tail region is absent (Figure 27). The growth complementation of E.
coli AS17 at 42ºC with pLICMtop-840t was partial compared to pLIC/pBADthio control
and pLICMtopI/pBADthio. However, it was also noticeable that in presence of the Rv1495
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toxin the partial complementation of pLICMtopI-840t is maintained and not diminished by
the presence of the toxin (Figure 28)
The growth complementation of E. coli AS17 at 42ºC with pLICMtopI-910t was better
compared to pLICMtopI-840t, and not difference in growth complementation was detected
when the toxin was present (Figure 29). These results indicate that the presence of the Cterminal tail is required for the inhibition of MtopI activity by Rv1495.

Y342

934
Y342

910
Y342

Figure 27. Truncated versions of Mtop I
Mtop I is composed of two main domains: N- terminal domain and C-terminal domain.
Each domain is divided in subdomains, different versions of C-terminal domain were
designed to test Mtop IA truncated versions activity inhibition by Rv1495 toxin. The
positively charged C-terminal tail is missing in the Mtop I 910t version while in Mtop I
840t version a larger portion is missing: D8+tail.
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Figure 28. Growth complementation of E. coli AS17 with pLICMtopI-840t
1).AS17/pLIC/pBADthio 2).AS17/pLICMtop I/pBADthio 3).AS17/pLICMtop I/pBADRv1495
4).AS17/pLICMtopI-840t/pBADthio
clone
2
5).AS17/pLICMtopI840t/pBADthio clone 3 6).AS17/pLICMtopI-840t/pBAD-Rv1495. Serial dilution of
E.coli AS17 cells were spotted on LBN agar plates (kanamycin 50 μg/ml and carbenicillin
100 μg/ml) containing arabinose 0.2%. The plate was inoculated by duplicate and
incubated at 30ºC (on the left) and 42ºC (on the right). E.coli AS17 cells containing Mtop
IA full lenght and Rv1495 toxin were used as control since the inhibitory effect was
demonstrated previously. Partial growth complementation of E. coli AS17 with
pLICMtopI-840t was not reversed in presence of Rv1495 toxin.
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Figure 29. Growth complementation of E. coli AS17 with pLICMtopI-910t
1).AS17/pLIC/pBADthio 2).AS17/pLICMtop I/pBADthio 3).AS17/pLICMtop I/pBADRv1495 4).AS17/pLICMtopI-910t/pBADthio 5).AS17/pLICMtopI-910t/pBAD-Rv1495.
Serial dilution of E.coli AS17 cells were spotted on LBN agar plates (kanamycin 50 μg/ml
and carbenicillin 100 μg/ml) containing arabinose 0.2%. The plate was inoculated by
duplicate and incubated at 30ºC (on the left) and 42ºC (on the right). E.coli AS17 cells
containing Mtop IA full lenght and Rv1495 toxin were used as control since the inhibitory
effect was demonstrated previously. Partial growth complementation of E. coli AS17 with
pLICMtopI-910t was not reversed in presence of Rv1495 toxin.

42/30oC growth complementation ratio of E. coli AS17 with truncated versions
of Mtop I-840t in the presence and absence of the Rv1495 toxin
The pLICMtopI-840t plasmid complemented partially the growth of E. coli AS17 at 42ºC
(Figure 28). In an alternative approach, the cell dilutions were also spread in LBN plates
with kanamycin (50 μg/ml), carbenicillin (100 μg/ml) and 0.2% arabinose for colony
counting and calculation of the 42/30oC ratio of each strain. As shown in Table 1, the
closest the 42/30oC ratio to 1 the better the complementation of cell growth at 42ºC in
presence of the respective plasmid. The growth complementation of AS17
pLICMtopI/pBADthio showed a 42/30oC ratio of 1, indicating a complete growth
complementation at 42ºC. However, when the toxin Rv1495 was present the 42/30oC ratio
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dropped to 10-5; the presence of the Rv1495 toxin prevented the growth complementation
at 42ºC. These results were previously documented in the growth complementation assay.
With regard to the AS17 pLICMtopI-840t/pBADthio, the growth complementation at 42ºC
was weak, but indeed comparable to pLICMtopI-840t/pBAD-Rv1495, suggesting that
Rv1495 is not interacting with MtopI-840t to inhibit its function.

Table 1. 42/30 ºC ratio of E. coli AS17 pLICMtop I 840t
E. coli AS17
cfu/ml
42/30 °C ratio
30 °C
pLIC/pBADthio
1x109
10-6
pLICMtop/pBADthio
2.8x108
1
pLICMtop/pBAD-Rv1495
1.4x108
10-5
pLICMtop 840t/pBADthio
2.5x108
10-5
pLICMtop 840t/pBAD-Rv1495
2.1x108
10-5
42 °C
pLIC/pBADthio
1x102
pLICMtop/pBADthio
2x108
pLICMtop/pBAD-Rv1495
3x103
pLICMtop 840t/pBADthio
2x103
pLICMtop 840t/pBAD-Rv1495
3.7x103
In the 42/30 ratio only exponential number was included.

Rv1495 Expression and purification
The Rv1495-GST fusion protein correspond to a 37 kDa protein; In Figure 30a, visible
the band corresponding to this protein is visible in the whole cell lysate as well as in the
soluble lysate confirming that the protein is soluble. Thirteen eluted fractions containing
the protein were collected and divided in two different pools (pool 5 and pool 8), which
were dialyzed in storage buffer and stored at -80ºC (Figure 30b and c).
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Figure 30. Rv1495-GST expression and purification
(A) Protein fractions after expression and before DNA purification to confirm presence of
Rv1495-GST (37 kDa) in the whole cell (WC) as well as in the soluble fraction (SL).
Protein ladder (PL) (B) First batch of eluted fraction pooled together before dialysis (pool
5) (C) Second batch of eluted fraction pooled together before dialysis (pool 8)
Discussion
We have demonstrated that the Rv1495 toxin is most likely interacting with the Cterminal tail of Mtop IA. As stated before, the C-terminal tail in Mycobacterial
topoisomerase IA may not be important for cleavage and rejoining of DNA, but plays an
important role in DNA strand passage, being then important for the enzyme processivity
(Ahmed, Bhat et al. 2013). Moreover, the C-terminal tail would interact in vivo with RNA
polymerase in M. smegmatis and M. tuberculosis strains in order to play an important role
in the rewinding of ssDNA when it exits the transcriptional bubble (Banda, Cao et al.
2017).
According to our results the MazF toxin may be inhibiting the strand passage, Hence
the enzyme would cleave and religate DNA continuously, but with no change in linking
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number generated. As a consequence, the relaxation activity of MtopI would be diminished
in presence of Rv1495.
Significantly, this interaction suggests an opportunity for the design of inhibitors of
MtopI that can be used to develop therapeutics specific for mycobacteria. Such therapeutics
would be less damaging for the normal human microbiome. The purified Rv1495 toxin
will be co-crystalized with MtopI by our collaborator Dr. Kemin Tan at Argonne National
Lab in order to characterize in greater detail the interactions responsible for the inhibition
of MtopI.
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3. Ethacridine is a Potent Inhibitor of Mycobacterial Topoisomerase I and Enhances
Moxifloxacin Lethality
Background Information
A collection of 1389 compounds was assembled by TB Alliance, a non-profit
organization dedicated to anti-TB drug discovery, and a subset of hits from NIH screening
of inhibitors of M. tuberculosis H37Rv growth at Southern Research Institute (Maddry,
Ananthan et al. 2009). They inhibited growth by 85-90% compared to untreated controls
in liquid cultures at <10 µM against M. tuberculosis H37Rv and >50 µM against
mammalian cells. The cellular targets of these inhibitors are largely unknown. In our
laboratory, topoisomerase I relaxation activity assays were conducted to determine if any
of the compounds among the 1389 compounds assembled by TB Alliance can inhibit the
catalytic activity of MtopI. We found that ethacridine is a potent inhibitor of the MtopI
relaxation activity (IC50 = 0.6 µM). The presence of three aromatic rings in the structure
of Ethacridine is important for activity (Figure 31a).
B)

A)

Ethacridine

m-AMSA

Figure 31. Ethacridine and m-AMSA structures
An established eukaryotic type II topoisomerase poison inhibitor m-AMSA, is used for
cancer treatment and have been also repurposed as Mtop IA inhibitor. This compound has
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a similar structure to ethacridine (Figure 31b). m-AMSA inhibits Mtop IA DNA relaxation
activity completely at 10 µM and the MIC values for M. smegmatis and M. tuberculosis
are 60 µM and 125 µM, respectively (Godbole, Ahmed et al. 2014). However, as stated
before the activity of Ethacridine as antimycobacterial agent is superior and worth it of
further investigation.

Research objectives
To explore the mechanism of action of Ethacridine, an FDA approved drug, as a
potential antimycobacterial agent.
•

To evaluate the Ethacridine mechanism of resistance and mode of action by
isolating and characterizing resistant mutants

•

To evaluate the potentiation of Moxifloxacin (a second line drug for TB
treatment) by Ethacridine against mycobacteria, using M. smegmatis mc2 155
as model.

Material and Methods
Resistant mutant isolation
M. smegmatis Ethacridine resistant mutants were isolated in LB plates containing 64X
MIC of Ethacridine (400 µM). Drug resistance was confirmed in Middlebrook 7H9 agar
plates containing 0.2% glycerol and supplemented with 10% albumin, dextrose and sodium
chloride (ADN) that also had the same concentration of Ethacridine used for resistant
mutants’ isolation. Previous attempts in the lab for isolation of Ethacridine resistant
mutants on LB plates containing lower Ethacridine concentration did not result in stable
resistant mutants that could be confirmed for growth in liquid media containing Ethacridine.
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Whole Genome Sequencing (WGS)
The Ethacridine resistant mutants were sequenced in collaboration with the Sanford
Burnham Prebys Medical Discovery Institute, Orlando, FL. Genomic DNA extraction was
performed at FlU. Mycobacterium smegmatis WT and mutant strains were cultured in 5
ml of Middlebrook 7H9 ADN. After two days of incubation, 2 ml of cells were spun down
at 16,000 rcf per min for DNA extraction. DNA extraction was performed using the
BACTOZOLTM Bacterial DNA isolation kit (Molecular Research Center). Following
DNA solubilization, the DNA quality and concentration were evaluated. DNA quality and
concentration were evaluated through the UV Absorbance 260/280 ratio (>1.8).
Genomic DNA was sent to Sanford Burnham Genomics and Bioinformatics Division for
sequencing; Illumina MiSeq® Next Generation Sequencer and Nextera XT library
preparation kit was used for WGS and SoftGenetics NextGENe Software used for data
analysis. Sequence of wild-type M. smegmatis mc2 155 (WT) from our lab was used as
reference for alignment of all mutant sequences.

Minimal Inhibitory concentration (MIC)
M. smegmatis strains were inoculated from LB/NaCl agar plates into 5 ml of
Middlebrook 7H9 broth containing 0.2% glycerol, 0.05% Tween 80 and supplemented
with ADN at 37°C with shaking. Cells were grown until stationary phase, diluted to optical
density (O.D600nm) 0.1 and diluted once again 1:10 in fresh Middlebrook 7H9 broth
containing 0.2% glycerol, 0.05% Tween with AND supplement. Fifty microliters of cells
were then transferred to each well of a 96-well plate containing 50 μl of serially diluted
compounds along the ordinate. An additional well containing 50 μl of media without any
compound was also inoculated with 50 μl of cells corresponding to the growth control. The
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96 well plate was incubated at 37°C with shaking. After 48 hours of incubation, 10 μl of
0.02% resazurin was added to the each well in the 96 well plate containing 100 μl of
cultured cells in presence of diluted compounds. The fluorescence reading at 560/590 nm
(excitation/emission) was taken after 5h of incubation at 37°C.

Survival assays
M. smegmatis strains (WT and Ethacridine resistant mutants) were cultured from
LB/NaCl plates to Middlebrook 7H9 broth containing 0.2% glycerol, 0.05% Tween 80 and
with ADN supplement at 37°C with shaking. The night before the assay, bacterial cells
were cultured in Middlebrook 7H9 broth containing 0.2% glycerol and 0.05% Tween 80
at 37°C with shaking. When cells reached exponential phase, optical density (O.D600nm)
0.5-0.8, were adjusted to (O.D600nm) 0.5 and diluted 1:10 in Middlebrook 7H9 broth
containing 0.2% glycerol and 0.05% Tween 80. Fifty microliters of cells were then
transferred to a clear round-bottom 96-well plate containing 50 μl of serially diluted
compounds. An additional well containing 50 μl of media without any compound was also
inoculated with 50 μl of cells and used as growth control. The 96 well plate was incubated
at 37°C with shaking.
From the 96 well plate, treated and untreated cells (control) were diluted and spread for
cell bactericidal effect evaluation. At time point 0h, cells in the control well were diluted
up to 10-4 in 1.5 ml tubes (final volume 1 ml) and 0.1 ml plated on LB/NaCl agar plates to
calculate the number of cells added (approximately 5x106 cfu/ml). Cells incubated in
presence of Ethacridine 6.25 μM, Moxifloxacin 0.16 μg/ml (2X MIC) and Moxifloxacin
0.16 μg/ml/Ethacridine 6.25 μM were diluted and 0.1 ml plated on LB/NaCl agar plates at
different time points (3, 6, 8, 9 and 12 hours). The cell survival percentage was calculated
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by dividing the number of treated cells that survived the treatment by the total number of
cells at time 0h.

Checkerboard assay
M. smegmatis mc2 155 strain was cultured as previously described for MIC assay and
50 μl of cells transferred to each well of a clear round-bottom 96-well plate containing 50
μl of serially diluted compounds. Ethacridine was diluted along the ordinate while
Moxifloxacin along the abscissa, as shown in Table 2. The 96 well plate was incubated at
37°C with shaking. After 48 hours of incubation, 10 μl of 0.02% resazurin was added to
each well of the 96 well plate containing 100 μl of cultured cells in presence of diluted
compounds. The fluorescence reading at 560/590 nm (excitation/emission) was taken after
5h of incubation at 37°C. The data generated was analyzed through the calculation of the
Fractional Inhibitory Concentration (FIC), which allows the classification of the
combinatory effect as: synergistic, additive, indifferent or antagonistic (Figure 32).
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Table 2. Checkerboard assay for Ethacridine and Moxifloxacin
Ethacridine

1
A

2

3

4

5

6

7

8

0.01 µg/ml

0.02 µg/ml

0.04 µg/ml

0.08 µg/ml

0.16 µg/ml

0.32 µg/ml

0.64 µg/ml

9

25 µM

B

12.5 µM

C

6.25 µM

D

3.125 µM

E

1.56 µM

F

0.78 µM

G

0.39 µM

H

Only Cells

Moxifloxacin

Distribution of drug dilution in a 96 wells plate

!"# =

&"# ' ()*+,-./,)- &"# 3 ()*+,-./,)+
&"# ' .0)-1
&"# 3 .0)-1

FIC value

Interpretation

≤ 0.5

Synergy

>0.5-1.0

Additive

1-4

Indifference

>4

Antagonism

Figure 32. FIC Calculation and Interpretation.
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10

Results
Ethacridine resistant mutant isolation and mutation frequency
Two stable resistant isolates, mutant 3 and mutant 13, were isolated at 64X MIC
Ethacridine. The mutation frequency for resistance to Ethacridine was found to be 5x10-9.

Mutations detected in WGS of drug resistant mutant strains
The mutations detected in mutant 3 and mutant 13 are shown in Table 3. There are
four common mutations were detected in mutant 3 and 13: a synonymous mutation on 4hydroxybenzoate transporter (no shown in the tables), and three non-synonymous
mutations, first in MSMEG_2106, a transcriptional regulator, a second one in
MSMEG_2945 ruvB gene coding for helicase of RuvAB Holliday junction resolvase, and
the third one corresponded to a deletion in MSMEG_0318 gene; which codes for an AMP
dependent synthetase and ligase. Mutation in MSMEG_6071 coding for TrmH family
RNA methyltransferase was found in mutant 3 but not mutant 13.

Mutation in

MSMEG_1523 rpsD gene coding for 30S non-ribosomal protein S4 was found in mutant
13 and not mutant 3.
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Table 3. Mutations associated with Ethacridine resistance
Gene

Homolog in
M.tuberculosis

Region

Freq

Type

Nucleotide
Ref

Allele

Amino acid
Ref

Allele

Functional
annotation in
M. smegmatis

Functional
annotation in M.
tuberculosis

MSMEG_2106

Rv3066

2184689

2

SNV

C

A

F

L

Putative
transcriptional
regulator

TetR
transcriptional
regulator that
controls the
expression of the
Mmr multidrug
efflux pump

MSMEG_2945

Rv2592c

3005678

2

SNV

G

T

M

I

ruvB
Holliday
junction
DNA
helicase RuvB

ruvB Holliday
junction
DNA
helicase RuvB

MSMEG_0318

No

353901

2

DEL

CGT

delCGT

fs

AMP dependent
synthetase
and
ligase

30S ribosomal
protein S4 RpsD.
This protein binds
directly to 16S
ribosomal RNA.
Possible
tRNA/rRNA
methyltransferase

MSMEG_1523

Rv3458c

1613303

1

SNV

A

G

D

G

rpsD
30S
ribosomal protein
S4 rpsD

MSMEG_6073

Rv3579c

6137851

1

SNV

G

A

G

R

TrmH
family
RNA
methyltransferase

Ref: reference; SNV: single nucleotide variation; DEL: deletion; fs: frame shift
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N/A

MIC of M. smegmatis WT and Ethacridine resistant mutants 3 and 13: Crossresistance to other antimicrobial agents.
Both Ethacridine resistant mutants 3 and 13 showed a two fold increase in Ethacridine
MIC compared to the WT strain. Assay of cross-resistance Table 4 revealed that mutant 13
does not have cross resistance to other drugs, however mutant 3 has around two-fold
increased resistance to Moxifloxacin and Streptomycin compared to the WT strain. This
may be due to the mutation in TrmH family RNA methyltransferase found in mutant 3.
Table 4. Cross-resistance to Moxifloxacin
Strain

Ethacridine

Moxifloxacin

Streptomycin

MIC (µM)

MIC (µg/ml)

MIC (µg/ml)

12.5

0.08-0.16

0.25-0.5

M. smegmatis mut 3

25

0.16

0.5-1

M. smegmatis mut 13

25

0.08-0.16

0.25-0.5

M. smegmatis WT

Combinatory effect of Moxifloxacin/Ethacridine on killing of M. smegmatis
The RuvAB Holliday junction resolvase has been shown previously to be involved in
killing of M. smegmatis by fluoroquinolones that inhibit the type IIA topoisomerase DNA
gyrase (Long, Du et al. 2015) and may also be involved in the killing of M. smegmatis by
topoisomerase IA inhibitors. Interestingly, we found an increase in moxifloxacin lethality
(2X MIC) in presence of Ethacridine 6.25 μM (Figure 33). Calculation of FIC was used
to evaluate the Ethacridine-Moxifloxacin combination on cell growth inhibition. The MIC
for each drug alone and in combination was the same, so the total for the FIC was 2 and
according to the previous description a value between 1-4 is classified as indifference.
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Figure 33. Effect of Moxifloxacin-Ethacridine combination in M. smegmatis survival
Survival assay performed in Middlebrook 7H9 NO ADN revealed that when
Ethacridine (6.25 μM) is combined with Moxifloxacin (0.16 μg/ml) the M.
smegmatis lethality is increased compared to the lethality generated by each drug
alone.
Discussion
Ethacridine’s ability to inhibit M. tuberculosis growth and Mtop IA activity in vitro, as
well as the fact it is an FDA approved drug merit further investigation of Ethacridine in
drug repurposing for anti-TB treatment. Ethacridine is currently used as anti-septic in
wounds and as an abortive agent (PubChem 2017) . In this project, the potential of
Ethacridine as antimycobacterial agent was highlighted. Using M. smegmatis as a model
to evaluate the bactericidal effect of this antimicrobial drug, it was found that ethacridine
is bactericidal and additionally can be combined to further improve the bactericidal
outcome with moxifloxacin, a second-line drug currently used for TB treatment. In fact,
there are studies that highlight the relevance of using fluoroquinolones in combination with
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new drugs and repurposed agents in first line phase for shortening of TB treatment as well
as in the treatment of drug resistant TB (Gillespie 2016, Yew and Koh 2016, Laughon and
Nacy 2017). One of the studies involved the use of Rifapentine-Moxifloxacin for drug
sensitive TB and also the use of pretomanid-moxifloxacin-pyrazinamide regimen (STAND
trial), which was replaced by BPaMZ regimen that includes also included bedaquiline.
BPaMZ regimen has shown promising results, however the use of bedaquiline use in some
countries with high MDR rates has been delayed (Lessem, Cox et al. 2015); partly because
of side effects associated with bedaquiline. The ethacridine-moxifloxacin combination
should be tested in animal models and clinical studies because both of them are FDA
approved drugs and the ethacridine, included in the TB Alliance library, is active against
M. tuberculosis with relatively low cytotoxicity. It can be noted that Moxifloxacin and
Ethacridine show an indifferent effect according to the checkerboard assay as well as
potentiation in their bactericidal activity when they are combined.
Due to the different mutations detected in the resistant mutants, ethacridine drug
resistance cannot be associated with a specific mutation and the drug target is not clearly
elucidated. Mutation in Topoisomerase IA gene was not seen in the resistant mutants
characterized. This suggests that inhibition of MtopI by Ethacridine may depend on
interaction between Ethacridine and DNA. The resistance mutations identified provide
further information on drug resistance in mycobacteria in general or mechanisms of
resistance associated to ethacridine specifically. Moreover, the development of a mutation
on an essential gene that affect the cell survival has high likelihood to be costly and cells
has many alternative resistance mechanisms related to drug transport and efflux to resist
environmental toxins.
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According to the results obtained on the Ethacridine resistant mutants, the mutation on
MSMEG_2106, a putative transcriptional regulator in M. smegmatis may be the first line
mechanism of resistance developed by the cells. This transcriptional regulator homolog in
M. tuberculosis, Rv3066, has been characterized and classified as a TetR transcriptional
regulator, important in the regulation of multidrug efflux pump (Mmr efflux pumps).
Hence, drug efflux, a general mechanism, may be the primary mechanism of resistance
before developing any mutation associated to the drug target.
Mutation on ruvB gene, which codes for the helicase component of the RuvAB
complex, was also a common mutation detected in the ethacridine resistant mutants.
RuvAB is a protein complex important in the resolution of Holliday junctions during DNA
recombination. Previous studies have shown that inhibition of RuvAB complex in M.
smegmatis WT strains can potentiate Moxifloxacin cell lethality (Long, Du et al. 2015).
Long, Du et al reported that RuvA inhibition, either by insertion of a negative mutation or
interaction with small molecules, increases the moxifloxacin lethality in M. smegmatis.
The simultaneous inhibition of RuvAB complex during Moxifloxacin treatment would
cause impairment in a moxifloxacin DNA damage repair system requiring recombination.
The presence of additional mutations in the Ethacridine resistant strains makes it
difficult to associate the resistance pattern to only one of the mutations detected. In fact,
topoisomerase IA may be the drug target but because of the essential nature of this protein
in mycobacteria, no mutations can be generated. Although other mutations were detected
in resistant mutants, not all of them were discussed because they do not have homologous
genes in M. tuberculosis or were not found in both ethacridine resistant mutants.
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4. Mechanism

and

resistance

for

antimycobacterial

activity

of

a

fluoroquinophenoxazine compound

Background information
Previous studies focusing on discovery of bacterial topoisomerase I inhibitors allowed
the identification of a compound NSC649059 with inhibitory activity against E. coli
topoisomerase I (IC50 = 0.8-2.0 µM) (Yu, Zhang et al. 2017). The activity of this
fluoroquinophenoxazine derivated against topoisomerase I (Yu, Zhang et al. 2017) led to
the design, synthesis and evaluation of fluoroquinophenoxazine analogs to test their
activity against diverse topoisomerases. Indeed, other fluoroquinophenoxazine derivates
such as: A-62176 (Permana, Snapka et al. 1994, Kang, Kim et al. 2008) and A-85226 (Fan,
Sun et al. 1995) have been reported as anticancer activity (Figure 34). However, this class
of compounds has not been widely studied as antimicrobial agents.

Figure 34. Fluoroquinophenoxazine derivates
On the left, the chemical structure of two fluoroquinophenoxazines derivates that
has shown activity against diverse cancer cell lines. A-62176 has exhibit low IC50
values against cancer cells (between 0.87-4.34 µM). On the right, the structure of
a fluoroquinophenoxazine derivate that exhibited activity against E. coli
topoisomerase IA and was used for the design of analogs that may have activity
against bacterial topoisomerase IA such as FP-11g. (Yu, Zhang et al. 2017)

68

Among the set of fluoroquinophenoxazine analogs previously published in a
collaborative work between the Tse-Dinh lab and Dr. Dianqing Sun’s group at University
of Hawaii Hilo, compound (FP-11g), with a 6-bipiperidinyl lipophilic side chain (Figure
35), inhibited the catalytic activity of E. coli topoisomerase I with strong potency (IC50 =
0.48µM). However, the whole-cell antibacterial activity on E. coli WT was limited.
Interestingly, FP-11g showed promising antituberculosis activity (MIC = 2.5 µM, SI = 9.8).
The selectivity index is defined as IC50/MIC: IC50 for eukaryotic cells (toxicity) and MIC
for prokaryotic cells, in this case M. tuberculosis. SI values ranging from 10 are acceptable.

Figure 35. Schematization of fluoroquinophenoxazines synthesis
Fluoquinophenoxazines from the NSC649059 scaffold were designed to
improve the compound stability and solubility by introducing different amine
functionalities (9-11). (Yu, Zhang et al. 2017)
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Research objectives
To study the inhibitory effect and mechanisms of resistance associated with FP-11g
compound in mycobacteria:
•

To determine the growth inhibitory and bactericidal concentration of FP-11g
compound in M. smegmatis and M. abscessus strains.

•

To perform Whole Genome Sequence analysis of M. smegmatis mutants
resistant to FP-11g for further characterization of mechanisms associated with
resistance.

Material and Methods
MIC (minimum inhibitory concentration) against M. smegmatis and M.
abscessus
M. smegmatis mc2 155 (WT from ATCC) and FP-11g resistant mutants derived from
WT were cultured in 5 ml Middlebrook 7H9 broth containing 0.2% glycerol, 0.05% Tween
80 with or without a supplement of 10% albumin, dextrose, sodium chloride (ADN) at
37°C with shaking. Stationary phase bacteria cultures were adjusted to an optical density
(OD600) of 0.1 and subsequently diluted 1:10 using growth media. Fifty microliters (~105
cfu) of the diluted culture were transferred to the individual wells of a clear round-bottom
96-well plate containing 50 μl of serially diluted compounds. The 96-well plate was then
incubated at 37°C with shaking. After 48 hours of incubation, resazurin (final concentration
0.002%) was added to the individual wells and the fluorescence reading at 560/590 nm was
taken with a BioTek Synergy plate reader after approximately 5h of incubation at 37°C.
A clinical isolate of M. abscessus bacterium (isolated at the Columbia University
Medical Center) was cultured in Middlebrook 7H9 ADN broth it reached an optical density
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(OD600) of 1.0. The culture was then stored at -80°C as 1 ml aliquots containing 15%
glycerol. These frozen aliquots were subsequently used as the inoculum for M. abscessus
MIC assays. Prior to conducting each MIC assay, an aliquot of frozen M. abscessus was
thawed and diluted 1:100 in Middlebrook 7H9 broth. After dilution, the bacterial cells
(~105 cfu) were added to the wells of a 96-well plate containing the serially diluted
compounds as described for M. smegmatis cells and incubated at 37°C with no shaking for
48 h. Subsequently, resazurin (final concentration 0.005%) was added to each well and
fluorescence reading at 560/590 nm (excitation/emission) was taken after 24 h of
incubation at 37°C. On the day of each MIC assay, thawed inoculum of M. abscessus was
also serially diluted and spread plated on LB agar plates to confirm for the inoculum load
of ~105 cfu/well. MIC determination for each bacteria was repeated at least three times.

MIC (minimum inhibitory concentration) M. smegmatis pTA-M+ and pTAnol strains
M. smegmatis strains containing previously constructed plasmids in our laboratory
(Sandhaus, Annamalai et al. 2016) were used to test the inhibitory mechanism of FP-11g
against MtopI. M. smegmatis pTA-M+ contains a pKW08-Lx derived plasmid (Williams,
Joyce et al. 2010), in which the luciferase gene has been replaced by MtopI gene to be
under the control of the tetracycline-inducible Tet promoter. Hence, pTA-M+ strain
overexpresses Mtop I when the tetracycline inducer is added. On the other hand, the M.
smegmatis pTA-nol, a strain that contains the pKW08 plasmid with no insert (luciferase
luxAB genes removed) is used as a control. Both strains were grown in 5 ml of Middlebrook
7H9 ADN containing 50 μg/ml hygromycin antibiotic required for the selection of pKW08
plasmid. One day before the assay, fresh dilutions of the overnight cultures were made in
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Middlebrook 7H9 media without ADN, with 50 μg/ml hygromycin. Stationary phase
bacteria cultures were adjusted to O.D600 nm 0.1 and further diluted 1:10 in Middlebrook
7H9 without ADN, with 50 μg/ml hygromycin and 20 ng/ml tetracycline. After O.D.
adjustment and dilution, 50 μl of cells were transferred to each well of a clear round-bottom
96-well plate containing 50 μl of diluted FP-11g compound. The 96 well plate was
incubated at 37°C without shaking. After 48 hours of incubation, 10 μl of resazurin 0.01%
was added to each well of the 96 well plate containing 100 μl of cultured cells in presence
of diluted compounds. The fluorescence reading at 560/590 nm was taken after
approximately 5h of incubation at 37°C.

Survival assay M. smegmatis and M. abscessus
The bactericidal effect of FP-11g compound was evaluated in 96-well plates using a
protocol similar to the MIC assay. In brief, M. smegmatis was incubated at 37°C with
shaking in the presence of 1X, 2X, 4X and 8X MIC of FP-11 g for 6, 10, 24 and 48 hours;
M. abscessus was incubated at 37°C without shaking in the presence of 1X and 2X MIC
of FP-11g for 24, 48 and 72 hours. At each time point 20 µl from the treatment wells were
serially diluted (10 fold), spread on LB agar plates and incubated at 37°C for 4 or 7 days
for counting the viable colonies of M. smegmatis and M. abscessus respectively. Ten
microliters from the treatment wells were also enriched in 5-ml of Middlebrook 7H9 broth
if there are no viable colonies from a particular treatment-time combination on the LB agar
plates. The survival percentage was calculated by dividing the number of viable colonies
at each time point by the initial viable count prior to the treatment (time 0). Survival assays
were repeated three times.
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Resistant mutants isolation
M. smegmatis mc2 155 (from ATCC) was exposed to increasing concentrations of the
antibacterial compound (FP-11g) in order to isolate mutant strains with different levels of
resistance through stepwise exposure (Fujimoto-Nakamura, Ito et al. 2005). M. smegmatis
WT mc2 155 strain was first cultured in 5 ml of 7H9 ADN with no compound. After two
days growth was visible and fresh 7H9 ADN media with no compound was inoculated by
making 1:100 dilutions. Next day when the growth was visible, the O.D600nm of the culture
was measured and adjusted to 0.1 using 7H9 ADN media. In total, 2x106 cells (100 µl of
O.D. 0.1 adjusted culture) were spread on 7H9 ADN agar containing 8X MIC (2.5 μM)
FP-11g for isolation of resistant mutants and calculation of mutation frequency. The
isolated mutants were steaked on fresh 7H9 ADN agar and inoculated in 2ml of liquid 7H9
ADN, both containing 8X MIC (2.5 μM). Only one of the mutants grew in liquid media
and was considered an actual resistant mutant. When growth was visible in liquid media,
the culture was spun down, and the pellet used to inoculate fresh media containing 16X
MIC FP-11g. After bacteria cells grew, a fraction of the culture was plated on 7H9 ADN
agar with no compound to isolate single resistant mutant colonies (PGM1, PGM2 shown
in Table 6). The stepwise mutant isolation was repeated starting with 4X MIC to isolate
additional resistant mutants (PGM3 – PGM6 shown in Table 6).

Genomic DNA extraction
M. smegmatis WT and mutant strains were cultured in 5 ml of Middlebrook 7H9 ADN.
After two days of incubation, 2 ml of cells were spun down at 16,000 rcf per min for DNA
extraction. DNA extraction was performed using the BACTOZOLTM Bacterial DNA
isolation kit (Molecular Research Center). Following DNA solubilization, the DNA

73

quality and concentration were evaluated. DNA quality was evaluated through the UV
Absorbance 260/280nm ratio (>1.8) and DNA quantity was measured using a fluorescencebased Qubit® dsDNA BR (Broad-Range) Assay Kit (Thermofisher, Cat # Q32853).

Library preparation
The DNA concentration was first measured using the Qubit® dsDNA BR (BroadRange) Assay Kit and adjusted to 0.2 ng/μL with 10 mM Tris HCl pH 8.0. After
concentration adjustment, all the Genomic DNAs were quantified once again to confirm
the concentration. This process involved sequencing of 96 bacterial strains. The following
library preparation kits were used: Nextera XT DNA Library Prep Kit, 96 Indexes (FC131-1096) and Index Kit (96 Indexes) (FC-131-1002). Procedures followed in the Library
preparation were based on Illumina Nextera XT DNA Library Prep Kit Reference guide
(Document 15031942 v02, April 2017)

Tagmentation: Tagment DNA buffer (10 μL) and normalized genomic DNA (5 μL)
were added to each well of a new Hard-Shell skirted PCR plate and mixed by pipetting
using a multichannel pipette. Then, 5 μL of Amplicon Tagment Mix were added to each
well, pipetted 5 times to mix and the plate was sealed. The PCR plate was centrifugated at
280 x g at 20°C for 1 min and placed in the thermal cycler to run the tagmentation program:
•

55°C for 5 minutes

•

Hold at 10°C

The Neutralization Tagment buffer (5 μL) was added immediately to each well and
mixed by pipetting; the plate was sealed and centrifugated at 280 x g at 20°C for 1 min.
Afterwards, the plate was incubated at room temperature for 5 minutes.
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Amplification: Index primers were vortexed and placed in the columns and rows of a
TrueSeq Index Plate Fixture: Index 1 (i7) adapters placed in columns 1-12 and Index 2 (i5)
adapters in rows A-H. Five microliters of each index were dispensed; Index 1 (i7) adapter
down each column and index 2 (i5) adapter across each row. Using a multichannel pipette,
15 μL of Nextera PCR Master Mix were added to each well containing index adapter. The
plate was sealed, centrifugated at 280 x g at 20°C for 1 min. The plate was placed in the
thermal cycler and run the PCR program:
•

72°C for 3 minutes

•

95°C for 30 seconds

•

12 cycles of:

•

95°C for 10 seconds

•

55°C for 30 seconds

•

72°C for 30 seconds

•

72°C for 5 minutes

•

Hold at 10°C.

•

Total volume in each well of the plate: 50 μL

DNA Clean up: This step uses AMPure XP magnetic beads to purify the DNA library
and remove short library fragments. After amplification the 96 well plate was centrifuged
at 280 x g at 20°C for 1 min. A fraction of the PCR product (50 μl) from each well were
transferred to a new midi plate. Next, 30 μL AMPure XP beads were added to each well
and the plate sealed. The plate was shaken at 1800 rpm for 2 minutes and incubated at room
temperature for 5 minutes. In order to separate the liquid phase from the beads, the plate
was place on a magnetic stand for approximately 2 minutes until the liquid is clear. The
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supernatant was removed and discarded; afterwards the beads containing the DNA were
washed twice with 200 μl of fresh 80% ethanol and dried on the magnetic stand for 15
minutes with no shaking in this step.
The midi plate was removed from the magnetic stand, 52.5 μl of resuspension buffer
added to each well and the sealed plate shaken at 1800 rpm for 2 minutes. After 2 minutes
of incubation at room temperature the plate was placed again on the magnetic stand for the
separation of magnetic beads. The supernatant from each well was collected in a new PCR
plate for further analysis.

Bioanalyzer analysis: In our process, 20 random samples of the cleaned-up libraries
were selected for the Bioanalyzer analysis and all them showed good tagmentation with
fragments sizes starting at 400 bp (average fragment sizes for our two set of samples were
668 and 634.1 bp respectively). A typical example of the library size distributions of one
of the 20 samples is shown in Figure 36.
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Figure 36. Library size distribution
Peaks showing ten different fragments sizes as well as the concentration (pg/μl)
of each peak are shown. High size fragments prevail confirming the quality of the
sample for WGS. No overtagmentation is acceptable for sequencing.

Normalization and pooling: As a first step in the normalization procedure, Qubit
assay is used to quantify (ng/ul) the cleaned-up DNA libraries.
Calculation of molar concentration of the libraries: Based on the average size of
fragments estimated from the bioanalyzer run and the DNA concentration (ng/l),
nanomolarity (nM) of the libraries are calculated as:
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nM = concentration (ng/ μL) * 1x106 μL/1L * bp mol/ 660 g * 1/Bioanalyzer average
size
After calculating the molarity, Illumina protocol gives options for manual or beadbased normalization based on the DNA yield. It is recommended that when a library yield
is less than 10-15 nM, normalization should be done manually. Our final library yield was
diverse with concentrations between 1.7 to 23.2 nM; Hence, normalization needed to be
done manually. Based on the yield, libraries can be normalized at four different
concentrations: 4 nM, 2 nM, 1 nM or 0.5 nM. As our libraries had concentration as low as
1.7, they were normalized to 1 nM in a 96-well PCR plate (Final volume per well =50 µl).
All the necessary dilution calculations were done using Microsoft Excel program. A sample
of the normalization calculations is shown in Table 5.
After samples are normalized to the same concentration (1 nM); these were pooled
together as follow: Using a multichannel pipette 5 μL were transfered from each well to
the first row in a fresh 96 well plate. The entire pooled libraries combined in row A 1-12
were transferred in a 0.5 ml tube. Final volume: 480 μL (5 μL x 96, or in this case 40 ul x
12).
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Table 5. Normalization of samples for Whole Genome Sequencing
Sample
Name

PG1
PG2
PG3
PG4
PG5
PG6
PG7
PG8
TA1
TA2
TA3
TA4
PG9
PG10
PG11
PG12
PG13
PG14
PG15
PG16
TA5
TA6
TA7
TA8
PG17
PG18
PG19
PG20
PG21
PG22
PG23
PG24
TA9
TA10
TA11
TA12
PG25
PG26
PG27
PG28
PG29
PG30
PG31
PG32
TA13
TA14
TA15

Orig. Conc.

Conversion

Final Conc.

Final Vol.

Vol of C1

Added Vol

C1 (ng/uL)
4.4
4.1
4.9
4.7
3.8
3.2
5.3
3.3
4.4
1.8
3.4
8.1
6.2
5.8
5.0
4.2
4.3
3.9
3.4
3.34
5.3
3.0
5.1
5.4
5.0
5.6
5.3
5.0
4.0
3.9
5.8
4.1
4.6
5.5
8.3
7.3
1.9
2.3
2.8
2.5
2.3
2.7
3.4
3.7
3.9
3.3
4.4

nM
9.9
9.2
11.1
10.8
8.7
7.3
12.0
7.4
10.5
4.4
8.2
19.3
14.0
13.1
11.3
9.5
9.9
8.9
7.7
7.6
12.7
7.2
12.1
12.9
11.4
12.6
12.1
11.3
9.1
8.8
13.1
9.3
11.0
13.2
19.8
17.5
4.3
5.3
6.3
5.6
5.3
6.2
7.7
8.3
9.3
7.8
10.4

C2 (nM)
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

V2 (uL)
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0

V1 (uL)
5.1
5.4
4.5
4.6
5.8
6.9
4.2
6.8
4.8
11.5
6.1
2.6
3.6
3.8
4.4
5.3
5.1
5.6
6.5
6.6
4.0
7.0
4.1
3.9
4.4
4.0
4.1
4.4
5.5
5.7
3.8
5.4
4.5
3.8
2.5
2.9
11.5
9.4
7.9
9.0
9.5
8.1
6.5
6.0
5.4
6.4
4.8

10mM Tris HCl (uL)
44.9
44.6
45.5
45.4
44.2
43.1
45.8
43.2
45.2
38.5
43.9
47.4
46.4
46.2
45.6
44.7
44.9
44.4
43.5
43.4
46.0
43.0
45.9
46.1
45.6
46.0
45.9
45.6
44.5
44.3
46.2
44.6
45.5
46.2
47.5
47.1
38.5
40.6
42.1
41.0
40.5
41.9
43.5
44.0
44.6
43.6
45.2
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Denaturation and Dilution of Libraries: steps followed here are based on Illumina’s
NextSeq System Denature and Dilute libraries guide (Document # 15048776 v02, January
2016). This protocol varies according to the concentration of normalized samples. Twenty
microliters of the pooled libraries (1 nM) were combined with equal volume (20 μL) of 0.2
N NaOH in a 1.5-ml centrifuge tube, vortexed, centrifugated at 280 x g for 1 min and
incubated at room temperature for 5 minutes. Next, 20 μL of 200 mM Tris-HCl pH 7.0
added to the library and vortexed briefly, centrifugated at 280 x g for 1 min. Pre-chilled
HT1 (940 μL) was added to the 20 pM denatured library and another cycle of vortexing
and centrifugation done. Finally, 450 μL were taken from the 20 pM library and added to
150 μL of pre-chilled HT1 to obtain a 15 pM denatured library. Six microliters of the PhiX
control were added to 594 μL of diluted (15 pM) library and the resultant mix loaded to the
pre-thawed reagent cartridge associated with the MiSeq Reagent kit v3.

Sequencing and Data Analysis
Illumina MiSeq® Next Generation Sequencer was used for WGS of all genomic DNA
previously normalized and pooled together. The PhiX Control v3 library was used in the
run. CLC genomics workbench 10 software (QIAGEN) was used for data analysis. M.
smegmatis WT sequence from our laboratory was used as reference to all mutant sequences.
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Results
Growth inhibition of M. smegmatis and M. abscessus
The MIC of FP-11g for M. smegmatis mc2 155 was found to be between 0.3-0.6 μM
in multiple measurements. For the clinical M. abscessus strain, the MIC was 50 μM,
compared to Clarithromycin MIC of 0.7-1.56 μg/ml (1-2 μM). IC50 for 50% growth
inhibition of the M. abscessus strain was estimated to be 3-6 μM.

MICs for M. smegmatis pTA-M+ and pTA-nol strains
The inhibitory effect of FP-11g was the same for both strains, MIC 0.3 μM.

Bactericidal activity of FP-11g
FP-11g showed strong bactericidal activity against M. smegmatis. When M. smegmatis
cells were exposed to 2X MIC of FP-11g the cell viability was diminished almost 5 Log
after 48 hours of incubation. For higher concentrations such as 4X MIC and 8X MIC, 24
hours were enough to diminish cell viability by more than 5 Log and the bactericidal effect
was complete at 48 hours, based on re-inoculation of non-diluted cultures in fresh
Middlebrook 7H9 ADN media (Figure 37). The effect on M. abscessus when cells were
exposed to 2X MIC of FP-11g corresponded to a diminished in cell viability above 3 Log
after 72 hours (

Figure 38) Because of the relatively high MIC value for M.

abscessus, higher concentrations were not tested in the survival assay.
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Figure 37. Bactericidal effect of FP-11g for M. smegmatis
1X (0.31 μM), 2X (0.625 μM), 4X (1.25 μM) and 8X (2.5 μM) MIC of FP11g were tested to determine their bactericidal effect on M. smegmatis at
different time points. FP-11g exhibited bactericidal effect even at 1X MIC,
reaching complete killing at 4X MIC after 24 hours.
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Figure 38. Bactericidal effect of FP-11g for M. abscessus
1X (50 μM) and 2X (100 μM) MIC of FP-11g were tested to determine their
bactericidal effect on M. abscessus at different times points. M. abscessus
strain grow slower than M. smegmatis strain, this is the reason for cell plating
up to 72 hours

Isolation and verification of resistant mutants
The mutation frequency for resistance to FP-11g at 8X (MIC) was estimated to be
5x10-7. Six M. smegmatis strains (PGM1 – PGM6, Table 6) isolated from stepwise increase
of FP-11g concentrations were verified to be resistant to the compound by determination
of MIC. An increase in the resistance to moxifloxacin was also observed but the foldincrease in moxifloxacin was significantly lower than the fold-increase for FP-11g MIC.
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Table 6. FP-11g resistant mutants, resistance levels and cross-resistance to Moxifloxacin

M. smegmatis
Strain

FP-11g
concentration for
mutant isolation
X MIC (0.31 μM)

FP-11g
MIC (μM)

Foldincrease in
FP-11g MIC

Moxifloxacin
MIC (μg/ml)

Foldincrease in
Moxifloxacin
MIC

WT

N/A

0.31

N/A

0.08-0.16

N/A

PGM1

8X → 16X

2.5

8X

0.16

2X

PGM2

8X → 16X

5

16X

0.32

4X

PGM3

4X → 10X

5

16X

0.32

4X

PGM4

4X → 13X

10

32X

0.32

4X

PGM5

4X → 16X

5

16X

0.32

4X

PGM6

4X → 16X

5

16X

0.16

2X

Mutations identified in WGS
The mutations found in each of the resistant strain are listed in Table 7. Mutations in
ten different genes were detected and associated with deletions, insertions or SNV (Single
Nucleotide Variations) Table 8. All the resistant strains have SNV on MSMEG_0965 gene
(mspA), which codes for the major porin in M. smegmatis. This porin is important for the
permeation of nutrients and antibiotics inside the cell. Previous studies showed that
deletion of this gene in M. smegmatis resulted in a reduced permeability to drugs such as
β-lactams, fluoroquinolones and chloramphenicol (Stahl, Kubetzko et al. 2001, Stephan,
Mailaender et al. 2004, Stephan, Bender et al. 2005, Danilchanka, Pavlenok et al. 2008)
The mspA gene is present in fast-growing mycobacterias only (including M. abscessus) and
is not found in M. tuberculosis (Kartmann, Stenger et al. 1999, Niederweis, Ehrt et al.
1999).
The second most frequent mutations (in 3 out of 6 mutants) detected correspond to
MSMEG_5623 and MSMEG_6430.

MSMEG_5623 gene codes for a L-carnitine

dehydratase homolog of unknown function in M. smegmatis, with no homolog in M.

84

tuberculosis according to Tuberculist (http://svitsrv8.epfl.ch/tuberculist/). However, using
the blast tool it was determined that this L-carnitine dehydratase homolog from M.
smegmatis has 32% identity when aligned with the L-carnitine dehydratase from M.
tuberculosis (Rv3272), including Asp33 (conserved amino acid) that corresponds to the
amino acid mutated in FP-11g resistant strains. MSMEG_6430, also a common mutation
detected, is classified as a membrane protein that may have diverse functions in the cells,
such as transportation of molecules through the membrane or serving as receptors for
chemical signals (Overington, Al-Lazikani et al. 2006, Adams, Worth et al. 2012).
Mutation was also detected in MSMEG_2820 which also codes for an unknown integral
membrane protein. The mutations in the membrane proteins detected here may affect the
transport of FP-11g across the membrane.
The rest of mutations were detected at lower frequencies. MSMEG_1513 codes for
a hypothetical protein with no homolog in M. tuberculosis and has been classified as an
oxidoreductase.

The MSMEG_0241 (Rv0202c) codes for MmpL11 (mycobacteria

membrane protein large), a protein that belongs to a family of transporters and contribute
to the cell wall biosynthesis in mycobacteria (Delmar, Chou et al. 2015). MmpL proteins
family has been associated with drug resistance in M. abscessus and M. tuberculosis
(Nessar, Cambau et al. 2012). MSMEG_0240 (homolog of Rv0201c) does not have known
function.
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Table 7. Mutations identified in each FP-11g resistant mutant

Strain
ID

PGM1

PGM2

PGM3

Region

Gene

Type

270553^270554

MSMEG_0241

1039173

Nucleotide

Amino acid

Ref

Allele

Ref

Allele

INS

-

C

L

fs

MSMEG_0965

SNV

T

C

L

P

6498888^6498889

MSMEG_6430

INS

-

C

S

fs

270553^270554

MSMEG_0241

INS

-

C

L

fs

1039173

MSMEG_0965

SNV

T

C

L

P

4715711^4715712

MSMEG_4629

INS

-

T

6498888^6498889

MSMEG_6430

INS

-

C

S

fs

6498891^6498892

MSMEG_6430

INS

-

C

D

fs

6498895

MSMEG_6430

SNV

G

C

S

C

6498901

MSMEG_6430

SNV

G

T

T

K

1013796

MSMEG_0933

DEL

C

-

R

fs
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Functional annotation
in M. smegmatis
MmpL11 protein.
Function unknown
Porin MspA
Hypothetical protein.
Function unknown. Integral
component of membrane
MmpL11 protein.
Function unknown
Porin MspA
pseudogene
Hypothetical protein.
Function unknown. Integral
component of membrane
Hypothetical protein.
Function unknown. Integral
component of membrane
Hypothetical protein.
Function unknown. Integral
component of membrane
Hypothetical protein.
Function unknown. Integral
component of membrane
Conserved
hypothetical protein.
Function unknown

PGM4

PGM5

PGM6

1039098

MSMEG_0965

SNV

C

T

T

I

2883459

MSMEG_2820

SNV

T

G

I

S

5707525

MSMEG_5623

SNV

C

A

D

Y

1039098

MSMEG_0965

SNV

C

T

T

I

1604708

MSMEG_1513

SNV

G

C

S

C

269640^269641

MSMEG_0240

INS

-

A

M

fs

1039098

MSMEG_0965

SNV

C

T

T

I

1604708

MSMEG_1513

SNV

G

C

S

C

5707525

MSMEG_5623

SNV

C

A

D

Y

1039098

MSMEG_0965

SNV

C

T

T

I

3612348

MSMEG_3552

SNV

C

G

E

Q

5707525

MSMEG_5623

SNV

C

A

D

Y

6498888^6498889

MSMEG_6430

INS

-

C

S

fs
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Porin MspA
Hypothetical protein.
Function unknown. Integral
component of membrane
L-carnitine
dehydratase. Function
unknown
Porin MspA
Conserved
hypothetical protein.
Function unknown.
oxidoreductase activity
Conserved
hypothetical protein.
Function unknown
Porin MspA
Conserved
hypothetical protein.
Function unknown.
oxidoreductase activity
L-carnitine
dehydratase. Function
unknown
Porin MspA
Conserved
hypothetical protein.
Function unknown
L-carnitine
dehydratase. Function
unknown
Hypothetical protein.
Function unknown. Integral
component of membrane

6498891^6498892

MSMEG_6430

INS

-

C

D

fs

6498895

MSMEG_6430

SNV

G

C

S

C

6498898^6498899

MSMEG_6430

INS

-

T

P

fs

6498901

MSMEG_6430

SNV

G

T

T

K

Ref: reference; SNV: single nucleotide variation; INS: insertion; DEL: deletion; fs: frame shift

\
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Hypothetical protein.
Function unknown. Integral
component of membrane
Hypothetical protein.
Function unknown. Integral
component of membrane
Hypothetical protein.
Function unknown. Integral
component of membrane
Hypothetical protein.
Function unknown. Integral
component of membrane

Table 8. Summary of mutations associated with FP-11g resistance in M. smegmatis
Gene

Homolog
in Mtb

Region

Freq

Type

MSMEG_0965

No

1039098

4

MSMEG_0965

No

1039173

2

MSMEG_2820

MSMEG_6430

MSMEG_6430

MSMEG_6430

No

No

No

No

2883459

6498888^6498889

6498891^6498892

6498895

1

3

2

2

Nucleotide

Amino acid

Ref

Allele

Ref

Allele

Functional annotation
in M. smegmatis

Functional annotation
in M. tuberculosis

SNV

C

T

T

I

Porin MspA

N/A

SNV

T

C

L

P

Porin MspA

N/A

S

Hypothetical protein.
Function unknown.
Integral component of
membrane

N/A

fs

Hypothetical protein.
Function unknown.
Integral component of
membrane

N/A

fs

Hypothetical protein.
Function unknown.
Integral component of
membrane

N/A

C

Hypothetical protein.
Function unknown.
Integral component of
membrane

N/A

SNV

INS

INS

SNV

T

G

-

C

-

C

G

C

I

S

D

S

MSMEG_6430

No

6498898^6498899

1

INS

-

T

P

fs

MSMEG_6430

No

6498901

2

SNV

G

T

T

K
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Hypothetical protein.
Function unknown.
Integral component of
membrane
Hypothetical protein.
Function unknown.

N/A
N/A

Integral component of
membrane
MSMEG_0241

Rv0202c

270553^270554

2

INS

-

C

L

fs

MmpL11 protein.
Function unknown

unknown/cell wall and
cellular processes

MSMEG_5623

No

5707525

3

SNV

C

A

D

Y

L-carnitine dehydratase.
Function unknown

N/A

MSMEG_0933

Rv0486

1013796

1

DEL

C

-

R

fs

Conserved hypothetical
protein. Function
unknown

mshA gene:
Glycosyltransferase

MSMEG_0240

Rv0201c

269640^269641

1

INS

-

A

M

fs

Conserved hypothetical
protein. Function
unknown

conserved hypothetical
/unknown

C

Conserved hypothetical
protein. Function
unknown.
oxidoreductase activity

N/A

MSMEG_1513

No

MSMEG_4629
MSMEG_3552

No

1604708

2

SNV

G

C

4715711^4715712

1

INS

-

T

3612348

1

SNV

C

G

S

E

Q

pseudogene
Conserved hypothetical
protein. Function
unknown

Freq: frequency; SNV: single nucleotide variation; INS: insertion; DEL: Deletion; Ref: reference; fs: frame shift
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N/A
N/A

5. Discussion
In previous studies, the FP-11g compound has been proposed as an antimycobacterial
agent active against M. tuberculosis (MIC = 2.5 µM) (Yu, Zhang et al. 2017). In this project
activity against the pathogenic non-tuberculosis mycobacteria (NTM) M. abscessus has
been demonstrated as well. Compounds active against both species would be useful in
clinical settings since in some cases the symptoms and clinical manifestations of infections
caused by these two organisms are undifferentiable, consequently empiric treatment is
required. Additionally, patients suffering cystic fibrosis or other immunosuppressive
condition can be infected by different organisms at the same time. In fact, co-infections
with M. abscessus and M. tuberculosis have been reported (Ishiekwene, Subran et al. 2017,
Sohn, Wang et al. 2017). The strong bactericidal effect against M. smegmatis make this
compound and its potential derivatives worthy of future studies for its use as an antimycobacterial agent. The finding of the growth inhibitory effect of FP-11g on M. abscessus
is encouraging because of the lack of response of NTM clinical strains and subspecies of
M. abscessus to all of the current antibiotics.
No specific mutations found in FP-11g M. smegmatis resistant mutants could be
definitiviely associated with the mechanism of action of this compound, but all of them
may play a role in drug resistance. Experiments in M. tuberculosis has shown that
expression of MspA porin promotes not only cell growth but also antibiotic susceptibility
(Mailaender, Reiling et al. 2004). No porin genes has been identified in M. tuberculosis
but some studies suggest the presence of these structures in this organism (Kartmann,
Stenger et al. 1999). The mutation in MspA porin is likely to be the first mechanism of
resistance developed by the cells, and hence the common mutation found. Changes in the
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porin may interrupt the drug transportation into the cell and support cell survival.). Since
this porin is found in fast growing mycobacteria, it would be of significance in the treatment
of atypical pathogenic mycobacteria including Mycobacterium abscessus studied here
(Cavalli, Reynaud et al. 2017).
Characterization of integral membrane proteins has been always a challenge due to
the difficulty for the expression, solubility and crystallization of these proteins. Most of the
information have been obtained through computational approaches, which predict the
structural conformation of a protein based on the primary sequence and classify the
different types of transmembrane proteins (Korepanova, Gao et al. 2005, Ding, Yuan et al.
2012). Transmembrane proteins could be associated with mechanisms of resistance to
drugs that are not targeting them directly. Integral component of membrane are channels
through the cellular membrane that transport amino acids, lipids, coenzymes,
carbohydrates, nucleotides and other metabolites (He and De Buck 2010). Mutations in
integral membrane proteins detected here may affect drug transportation through the
membrane. As mentioned before, any variation in channels that transport molecules
through the cell wall will affect the intake of molecules including drugs and metabolites.
These integral components of membrane could also be non-characterized efflux pumps that
may be extruding the drug from the organism and support the drug resistance.
In this study we detected the MmpL11 mutation in two resistant mutants. Previous
studies with M. tuberculosis strains containing mutations in MmpL proteins showed that
all the mutant strains retained general drug susceptibility to diverse antibacterial agents;
suggesting that MmpL proteins do not play a direct role in drug resistance (Domenech,
Reed et al. 2005). Nonetheless, recent studies have divided the MmpL family from M.
tuberculosis in two subgroups hydrophobe/amphiphile efflux (HAE) family that includes
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member of the MmpL family that transport fatty acids and the RND transporters
superfamily which include members of MmpL family associated with antibiotic efflux
(Sandhu and Akhter 2015). In M. abscessus, MmpL has been associated with drug
resistance through efflux pumps (Strnad and Winthrop 2018). Additionally, mutations on
MmpL11 proteins has been associated to impairment of biofilm formation in M. smegmatis
and absence of this gene has generated a reduced permeability to host antimicrobial agents
(Purdy, Niederweis et al. 2009, Pacheco, Hsu et al. 2013), which is an evidence that this
mutation may be playing a role in drug resistance.
Absence of mutations in topA gene in the resistant mutants isolated may be because
FP-11g acts as an unconventional catalytic inhibitor. These types of inhibitors are described
as compound that binds to the DNA as well as to the topoisomerase enzyme to inhibits the
topoisomerase activity (Akerman, Fagenson et al. 2014). Mutation that affect the essential
activity of topoisomerase I could compromise cell growth to a significant extent and would
less likely be selected for resistance than the mutations detected here that can limit
compound transport into the cell. Further studies are required to identify other analogs
FP11-g that can be confirmed more definitely as targeting topoisomerase I activity in its
antimycobacterial mechanism of action.
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